KR20180041361A - Organic compound and organic electroluminescent device using the same - Google Patents

Organic compound and organic electroluminescent device using the same Download PDF

Info

Publication number
KR20180041361A
KR20180041361A KR1020160133400A KR20160133400A KR20180041361A KR 20180041361 A KR20180041361 A KR 20180041361A KR 1020160133400 A KR1020160133400 A KR 1020160133400A KR 20160133400 A KR20160133400 A KR 20160133400A KR 20180041361 A KR20180041361 A KR 20180041361A
Authority
KR
South Korea
Prior art keywords
group
compound
aryl
mmol
core
Prior art date
Application number
KR1020160133400A
Other languages
Korean (ko)
Other versions
KR102673121B1 (en
Inventor
한송이
엄민식
조현종
Original Assignee
주식회사 두산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 두산 filed Critical 주식회사 두산
Priority to KR1020160133400A priority Critical patent/KR102673121B1/en
Priority to PCT/KR2017/011329 priority patent/WO2018070835A1/en
Publication of KR20180041361A publication Critical patent/KR20180041361A/en
Application granted granted Critical
Publication of KR102673121B1 publication Critical patent/KR102673121B1/en

Links

Classifications

    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • H01L51/0072
    • H01L51/5012
    • H01L51/5056
    • H01L51/5072
    • H01L51/5092
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/15Hole transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/16Electron transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/17Carrier injection layers
    • H10K50/171Electron injection layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/10Organic polymers or oligomers
    • H10K85/111Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

The present invention relates to a novel organic compound and an organic electroluminescent device using the same, and more specifically, to a novel organic compound with excellent luminous power, and an organic electroluminescent device having improved characteristics such as high luminous efficiency, low driving voltage, and long lifetime by containing the novel compound in one or more organic material layers.

Description

유기 화합물 및 이를 이용한 유기 전계 발광 소자{ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME}TECHNICAL FIELD [0001] The present invention relates to an organic compound and an organic electroluminescent device using the organic compound.

본 발명은 신규한 유기 화합물 및 이를 이용한 유기 전계 발광 소자에 관한 것으로, 보다 상세하게는 발광능이 우수한 화합물 및 이를 하나 이상의 유기물층에 포함함으로써, 발광효율, 구동전압, 수명 등의 특성이 향상된 유기 전계 발광 소자에 관한 것이다.The present invention relates to a novel organic compound and an organic electroluminescent device using the same. More particularly, the present invention relates to a compound having excellent light-emitting ability and a compound having at least one organic compound in the organic compound layer, Device.

1950년대 Bernanose의 유기 박막 발광 관측을 시점으로 1965년 안트라센 단결정을 이용한 청색 전기발광으로 이어진 유기 전계 발광(electroluminescent) 소자에 대한 연구는 1987년 탕(Tang)에 의하여 정공층과 발광층의 기능층으로 나눈 적층구조의 유기 전계 발광 소자가 제시되었다. 이후, 고효율, 고수명의 유기 전계 발광 소자를 만들기 위하여, 소자 내 각각의 특징적인 유기물층을 도입하는 형태로 발전하여 왔으며, 이에 사용되는 특화된 물질의 개발로 이어졌다.A study on organic electroluminescent devices that resulted in blue electroluminescence using anthracene single crystals in 1965 based on observation of organic thin film emission of Bernanose in the 1950s was made by Tang in 1987 divided by the functional layer of the hole layer and the light emitting layer An organic electroluminescent device having a laminated structure has been proposed. Thereafter, in order to form a high efficiency and high number of organic electroluminescent devices, each organic material layer has been developed into a form in which each organic material layer has been introduced into the device, leading to the development of specialized materials used therefor.

유기 전계 발광 소자에서는 두 전극 사이에 전압을 걸어 주면 양극에서는 정공이 주입되고, 음극에서는 전자가 유기물층으로 주입된다. 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다. 이때 유기물층으로 사용되는 물질은 그 기능에 따라, 발광 물질, 정공 주입 물질, 정공 수송 물질, 전자 수송 물질, 전자 주입 물질 등으로 분류될 수 있다.In the organic electroluminescent device, when a voltage is applied between two electrodes, holes are injected into the anode and electrons are injected into the organic layer at the cathode. When the injected holes and electrons meet, an exciton is formed. When the exciton falls to the ground state, light is emitted. The material used as the organic material layer may be classified into a light emitting material, a hole injecting material, a hole transporting material, an electron transporting material, and an electron injecting material depending on its function.

유기 전계 발광 소자의 발광층 형성재료는 발광색에 따라 청색, 녹색, 적색 발광 재료로 구분될 수 있다. 그밖에, 보다 나은 천연색을 구현하기 위한 발광재료로 노란색 및 주황색 발광재료도 사용된다. 또한, 색순도의 증가와 에너지 전이를 통한 발광 효율을 증가시키기 위하여, 발광 재료로서 호스트/도펀트 계를 사용할 수 있다.The light emitting layer forming material of the organic electroluminescent device can be classified into blue, green and red light emitting materials according to the luminescent color. In addition, yellow and orange light emitting materials are also used as light emitting materials for realizing better color. Further, in order to increase the color purity and increase the luminous efficiency through energy transfer, a host / dopant system can be used as a light emitting material.

도판트 물질은 유기 물질을 사용하는 형광 도판트와 Ir, Pt 등의 중원자(heavy atoms)가 포함된 금속 착체 화합물을 사용하는 인광 도판트로 나눌 수 있다. 이러한 인광 재료의 개발은 이론적으로 형광에 비해 4배까지의 발광 효율을 향상시킬 수 있어 인광 도판트 뿐만 아니라 인광 호스트 재료들에 대해 관심이 집중되고 있다.The dopant material can be divided into a fluorescent dopant using an organic material and a phosphorescent dopant using a metal complex compound containing heavy atoms such as Ir and Pt. The development of such a phosphorescent material can theoretically improve the luminous efficiency up to 4 times as compared with that of fluorescence, and attention is focused on phosphorescent host materials as well as phosphorescent dopants.

현재까지 정공 주입층, 정공 수송층. 정공 차단층, 전자 수송층으로 사용되는 물질은, 하기 화학식으로 표현된 NPB, BCP, Alq3 등이 널리 알려져 있고, 발광 물질로는 안트라센 유도체들이 형광 도판트/호스트 재료로서 보고되고 있다. 특히 발광재료 중 효율 향상 측면에서 큰 장점을 가지고 있는 인광 도펀트 재료로서는 Firpic, Ir(ppy)3, (acac)Ir(btp)2 등과 같은 Ir을 포함하는 금속 착체 화합물이 청색, 녹색, 적색 도판트 재료로 사용되고 있다. 현재까지는 CBP가 인광 호스트 재료로 우수한 특성을 나타내고 있다.Up to now, hole injecting layer, hole transporting layer. NPB, BCP, Alq 3 and the like represented by the following chemical formulas are widely known as substances used as a hole blocking layer and an electron transporting layer, and anthracene derivatives as a luminescent material have been reported as fluorescent dopant / host materials. As a phosphorescent dopant material having a great advantage in terms of efficiency improvement of a light emitting material, a metal complex compound containing Ir such as Firpic, Ir (ppy) 3 , (acac) Ir (btp) 2 and the like is a blue, green, It is used as a material. So far, CBP has shown excellent properties as a phosphorescent host material.

Figure pat00001
Figure pat00001

그러나, 종래 발광 물질들은 발광 특성 측면에서는 유리한 면이 있으나, 유리전이온도가 낮고 열적 안정성이 매우 좋지 않기 때문에, 유기 전계 발광 소자에서의 수명 측면에서 만족할만한 수준이 되지 못하고 있다. 따라서, 우수한 성능을 가지는 발광 물질의 개발이 요구되고 있다.However, conventional luminescent materials are advantageous from the viewpoint of luminescence characteristics, but they are not satisfactory in terms of lifetime in an organic electroluminescent device because the glass transition temperature is low and the thermal stability is not very good. Therefore, development of a luminescent material having excellent performance is required.

일본공개특허공보 제2001-160489호Japanese Patent Application Laid-Open No. 2001-160489

상기한 문제점을 해결하기 위해, 본 발명은 유기 전계 발광 소자에 적용할 수 있으며, 발광능이 우수한 신규 유기 화합물을 제공하는 것을 목적으로 한다.In order to solve the above problems, it is an object of the present invention to provide a novel organic compound which can be applied to an organic electroluminescent device and has excellent light emitting ability.

또한, 본 발명은 상기 신규 유기 화합물을 포함하여 낮은 구동전압과 높은 발광효율을 나타내며 수명이 향상되는 유기 전계 발광 소자를 제공하는 것을 또 다른 목적으로 한다.It is another object of the present invention to provide an organic electroluminescent device including the novel organic compound and exhibiting a low driving voltage and a high luminous efficiency and having an improved lifetime.

상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound represented by the following general formula (1).

[화학식 1][Chemical Formula 1]

Figure pat00002
Figure pat00002

상기 화학식 1에서,In Formula 1,

L1 및 L2는 서로 동일하거나 상이하며, 각각 독립적으로 단일결합이거나, 혹은 C6~C18의 아릴렌기 및 핵원자수 5 내지 18개의 헤테로아릴렌기로 이루어진 군에서 선택되고,L 1 and L 2 are the same or different and are each independently a single bond or a group selected from the group consisting of a C 6 to C 18 arylene group and a heteroarylene group having 5 to 18 nucleus atoms,

복수의 R1은 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기 및 C2~C40의 알키닐기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, 다만 적어도 하나 이상의 축합 고리를 형성하고,Plural R 1 are the same or different and are each independently hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group and C 2 ~ C Or an alkynyl group having 1 to 40 carbon atoms, or may be bonded to adjacent groups to form a condensed ring, but at least one condensed ring is formed,

B는 하기 화학식 2로 표시되는 치환체이고,B is a substituent represented by the following formula (2)

[화학식 2](2)

Figure pat00003
Figure pat00003

상기 화학식 2에서,In Formula 2,

*은 상기 화학식 1에 결합되는 부분을 의미하고,* Represents a moiety bonded to Formula 1,

X는 C(R3)(R4), O 및 S로 이루어진 군으로부터 선택되고,X is selected from the group consisting of C (R 3 ) (R 4 ), O and S,

Ar1 및 Ar2는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되고,Ar 1 and Ar 2 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C the group of boron 60 aryl, C 6 ~ C 60 aryl phosphine group, is selected from the group consisting of C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of,

m은 0 내지 3의 정수이고,m is an integer of 0 to 3,

R2 내지 R4는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있고, R 2 to R 4 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ alkenyl group of the C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C group of 60 arylboronic, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ selected from the group consisting of an aryl amine of the C 60 of or, or adjacent groups bonded fused to the A ring can be formed,

상기 L1 및 L2의 아릴렌기 및 헤테로아릴렌기와, 상기 Ar1 및 Ar2, R1 내지 R4의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.Wherein L 1, and arylene group of L 2 and a heteroarylene group, an alkyl group of said Ar 1 and Ar 2, R 1 to R 4, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, An alkyl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, A nitro group, a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C An aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 ~ C 60 aryl silyl group, C 1 ~ C 40 alkyl boron group, C 6 ~ C of the group 60 arylboronic of, C 6 ~ C 60 aryl phosphine group, C 6 ~ aryl phosphine oxide of the C 60 group And C 6 -C An arylamine group having 1 to 60 carbon atoms, and when the substituent is plural, they may be the same or different from each other.

또한, 본 발명은 양극, 음극 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하고, 상기 1층 이상의 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함하는 것인 유기 전계 발광 소자를 제공한다. 여기서, 상기 화학식 1로 표시되는 화합물을 포함하는 유기물층은 정공 주입층, 정공 수송층, 발광 보조층, 발광층, 전자 수송층 및 전자 주입층으로 이루어진 군에서 선택될 수 있다. 이때, 상기 화학식 1로 표시되는 화합물은 발광층의 인광 호스트로 사용될 수 있다.The present invention also provides an organic electroluminescent device comprising a cathode, a cathode, and at least one organic layer sandwiched between the anode and the cathode, wherein at least one of the one or more organic layers includes a compound represented by the general formula An electroluminescent device is provided. Here, the organic material layer including the compound represented by Formula 1 may be selected from the group consisting of a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer, and an electron injecting layer. At this time, the compound represented by Formula 1 may be used as a phosphorescent host of the light emitting layer.

본 발명의 화학식 1로 표시되는 화합물은 열적 안정성 및 발광 특성이 우수하기 때문에 유기 전계 발광 소자의 유기물층의 재료로 사용될 수 있다.The compound represented by the general formula (1) of the present invention has excellent thermal stability and luminescent properties and can be used as a material of an organic material layer of an organic electroluminescent device.

특히, 본 발명의 화학식 1로 표시되는 화합물을 인광 호스트 재료로 사용할 경우, 종래의 호스트 재료에 비해 낮은 구동전압, 높은 효율 및 긴 수명을 갖는 유기 전계 발광 소자를 제조할 수 있고, 나아가 성능 및 수명이 향상된 풀 칼라 디스플레이 패널도 제조할 수 있다.In particular, when the compound represented by Formula 1 of the present invention is used as a phosphorescent host material, an organic electroluminescent device having a lower driving voltage, higher efficiency, and longer lifetime than conventional host materials can be manufactured. Further, This improved full color display panel can also be manufactured.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

1. 신규 유기 화합물1. New organic compounds

본 발명에 따른 신규 유기 화합물은 '벤조카바졸(benzocarbazole)'에 '아크리딘(acridine), 페녹사진(phenoxazine) 또는 페녹시아진(phenothiazine)'이 직접 결합되거나 링커(예컨대, 아릴렌기 또는 헤테로아릴렌기)를 통해 결합된 형태를 기본 골격으로 하며, 이러한 기본 골격에 다양한 치환체가 도입되어 상기 화학식 1로 표시되는 것을 특징으로 한다. The novel organic compound according to the present invention can be produced by directly coupling 'acridine, phenoxazine or phenothiazine' to 'benzocarbazole' or linker (eg, arylene group or hetero Arylene group), and a variety of substituents are introduced into the basic skeleton to be represented by the formula (1).

구체적으로, 상기 화학식 1의 화합물은 승화성 및 우수한 열적 안정성을 갖는 아크리딘, 페녹사진 또는 페녹시아진을 포함한다. 이러한 화학식 1의 화합물을 유기 전계 발광 소자에 사용할 경우에는 소자의 수명이 연장되어 장기간 사용될 수 있다.Specifically, the compound of formula (1) includes acridine, phenoxazine or phenoxyazine having sublimation properties and excellent thermal stability. When the compound of Formula 1 is used in an organic electroluminescent device, the lifetime of the device is prolonged and can be used for a long time.

이러한 상기 화학식 1의 화합물은 아크리딘, 페녹사진 또는 페녹시아진이 '벤조카바졸'과 결합되어, '카바졸'과 결합된 경우에 비해 컨쥬게이션(conjugation) 길이가 증가하여 밴드갭(band gap)이 감소할 수 있다. 또한, 상기 화학식 1의 화합물은 벤조카바졸이 '아크리딘, 페녹사진 또는 페녹시아진'과 결합되어, '카바졸'과 결합된 경우에 비해 컨쥬게이션(conjugation) 길이가 증가하여 밴드갭(band gap)이 감소할 수 있다(하기 표 1 참조). 이와 같은 화학식 1의 화합물은 유기 전계 발광 소자의 유기물층 재료에 사용될 수 있으며, 이때 발광층 재료로 사용될 경우, 장파장을 나타내어 적색의 인광 호스트 재료로 사용될 수 있다.Compounds of formula (I) can be conjugated with acridine, phenoxazine or phenoxyazine to form benzoglucarb which is conjugated with band gap ) Can be reduced. In addition, the compound of Formula 1 is bonded to 'acridine, phenoxazine or phenoxyazine' by benzocarbazole to increase the conjugation length compared to the case of binding to 'carbazole' band gap can be reduced (see Table 1 below). The compound of Formula 1 may be used as an organic material layer of an organic electroluminescent device, and when used as a light emitting layer material, it may exhibit a long wavelength and be used as a red phosphorescent host material.

구조rescue

Figure pat00004
Figure pat00004
Figure pat00005
Figure pat00005
 
Figure pat00006
 
Figure pat00006
Figure pat00007
Figure pat00007
HOMOHOMO 5.02 eV5.02 eV 4.48 eV4.48 eV 5.04 eV5.04 eV 4.66 eV4.66 eV LUMOLUMO 2.01 eV2.01 eV 2.01 eV2.01 eV 2.10 eV2.10 eV 2.00 eV2.00 eV 밴드갭Band gap 3.01 eV3.01 eV 2.47 eV2.47 eV 2.94 eV2.94 eV 2.66 eV2.66 eV T1T1 2.37 eV2.37 eV 2.15 eV2.15 eV 2.42 eV2.42 eV 2.26 eV2.26 eV

또한, 상기 화학식 1의 화합물은 상기 기본 골격에 도입되는 다양한 치환기의 종류에 따라 HOMO 및 LUMO 에너지 레벨을 조절할 수 있으며, 넓은 밴드갭 뿐만 아니라 높은 캐리어 수송성을 가질 수 있다. 이러한 화학식 1의 화합물은 상기 기본 골격에 질소-함유 헤테로환(예컨대, 피리딘기, 피리미딘기, 퀴나졸린기, 트리아진기 등)과 같이 전자 흡수성이 큰 전자 끌개기(EWG)가 결합될 경우, 분자 전체가 바이폴라(bipolar) 특성을 갖기 때문에 정공과 전자의 결합력을 높일 수 있다. 이러한 화학식 1의 화합물은 유기 전계 발광 소자의 유기물층 재료, 특히 발광층 재료로 사용될 수 있다.In addition, the compound of Formula 1 can control HOMO and LUMO energy levels according to various types of substituents introduced into the basic skeleton, and can have a wide band gap as well as a high carrier transportability. When the electron donating group (EWG) having a high electron absorbing property such as a nitrogen-containing heterocycle (for example, a pyridine group, a pyrimidine group, a quinazoline group or a triazine group) is bonded to the basic skeleton, Since the entire molecule has a bipolar characteristic, the bonding force between holes and electrons can be enhanced. The compound of the formula (1) can be used as an organic material layer material of an organic electroluminescence device, particularly a light emitting layer material.

이와 같은 화학식 1로 표시되는 화합물은 종래 유기 전계 발광 소자용 재료[예: 4,4-dicarbazolybiphenyl (이하, ‘CBP’라 함)]보다 높은 분자량을 갖기 때문에, 유리전이온도가 높아 열적 안정성이 우수할 뿐만 아니라 발광능이 우수하다. 따라서, 상기 화학식 1의 화합물을 유기 전계 발광 소자의 유기물층에 적용할 경우에는 소자의 구동전압, 효율, 수명 등이 향상될 수 있다. 이러한 화학식 1의 화합물은 유기 전계 발광 소자의 유기물층 재료로 사용될 수 있으며, 바람직하게는 발광층 재료(청색, 녹색 및/또는 적색의 인광 호스트 재료)로 사용될 수 있다.The compound represented by the formula (1) has higher molecular weight than the conventional organic electroluminescent device material (for example, 4,4-dicarbazolybiphenyl (hereinafter referred to as "CBP")] But also has excellent luminous efficiency. Accordingly, when the compound of Formula 1 is applied to an organic material layer of an organic electroluminescent device, the driving voltage, efficiency, lifetime, etc. of the device can be improved. The compound of the formula (1) can be used as an organic layer material of an organic electroluminescence device, and can preferably be used as a light emitting layer material (blue, green and / or red phosphorescent host material).

따라서, 본 발명에 따른 화학식 1의 화합물을 포함하는 유기 전계 발광 소자는 성능 및 수명 특성이 크게 향상될 수 있고, 이러한 유기 전계 발광 소자가 적용된 풀 칼라 유기 발광 패널도 성능이 극대화될 수 있다.Accordingly, the organic electroluminescent device including the compound of Formula 1 according to the present invention can greatly improve performance and lifetime characteristics, and the full-color organic luminescent panel to which such an organic electroluminescent device is applied can also maximize the performance.

본 발명에 따른 신규 화합물은 벤조카바졸에 아크리딘, 페녹사진 또는 페녹시아진이 직접 결합되거나 링커를 통해 결합되면서 다양한 치환체가 도입되는 것으로, 상기 화학식 1로 표시된다.The novel compounds according to the present invention are represented by the above formula (1) in which various substituents are introduced into benzocarbazole through acridine, phenoxazine or phenoxyazine directly or through a linker.

구체적으로, 상기 화학식 1로 표시되는 화합물에서, L1 및 L2는 서로 동일하거나 상이하며, 각각 독립적으로 단일결합이거나, 혹은 2가의 연결기일 수 있다. 이때, 상기 2가의 연결기는 C6~C18의 아릴렌기 및 핵원자수 5 내지 18개의 헤테로아릴렌기로 이루어진 군에서 선택된다. 상기 아릴렌기 및 헤테로아릴렌기의 비제한적인 예로는 페닐렌기, 비페닐렌기, 나프틸렌기, 안트라세닐렌기, 인데닐렌기, 피란트레닐렌기, 카르바졸릴렌기, 티오페닐렌기, 인돌일렌기, 푸리닐렌기, 퀴놀리닐렌기, 피롤일렌기, 이미다졸릴렌기, 옥사졸릴렌기, 티아졸릴렌기, 트리아졸릴렌기, 피리디닐렌기, 피리미디닐렌기 등이 있다.Specifically, in the compound represented by Formula 1, L 1 and L 2 may be the same or different and each independently a single bond or a divalent linking group. Wherein the bivalent linking group is selected from the group consisting of C 6 to C 18 arylene groups and heteroarylene groups having 5 to 18 nuclear atoms. Examples of the arylene group and the heteroarylene group include a phenylene group, a biphenylene group, a naphthylene group, an anthracenylene group, an indenylene group, a pyranthrenylene group, a carbazolylene group, a thiophenylene group, An imidazolylene group, an oxazolylene group, a thiazolylene group, a triazolylene group, a pyridinylene group, a pyrimidinylene group and the like.

바람직하게는, 상기 L1 및 L2는 서로 동일하거나 상이하며, 각각 독립적으로 단일결합 또는 C6~C18의 아릴렌기일 수 있다.Preferably, L < 1 > and L < 2 > are the same as or different from each other, and each independently may be a single bond or a C 6 -C 18 arylene group.

복수의 R1은 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기 및 C2~C40의 알키닐기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, 다만 적어도 하나 이상 축합 고리를 형성한다.Plural R 1 are the same or different and are each independently hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group and C 2 ~ C Or an alkynyl group having 1 to 40 carbon atoms, or may be bonded to adjacent groups to form a condensed ring, but at least one condensed ring is formed.

바람직하게는, 상기 복수의 R1은 하나의 R1과 다른 하나의 R1이 결합하여 하나의 축합 고리를 형성하며, 나머지 R1은 수소일 수 있다. 이러한 화학식 1의 화합물은 하기 화학식 3 내지 8로 표시되는 화합물로 구체화할 수 있다.Preferably, the plurality of R 1 forms a fused ring one by one and the other of R 1 R 1 is bonded, and the remaining R 1 may be hydrogen. The compound of the formula (1) may be embodied as a compound represented by the following formulas (3) to (8).

X는 C(R1)(R2), O 및 S로 이루어진 군에서 선택된다.X is selected from the group consisting of C (R 1 ) (R 2 ), O and S.

Ar1 및 Ar2는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된다.Ar 1 and Ar 2 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C 60 arylboronic group, C 6 ~ C 60 aryl phosphine group, is selected from C 6 ~ C 60 aryl phosphine oxide group, and the group consisting of C 6 ~ C 60 aryl group of an amine of.

바람직하게는, 상기 Ar1 및 Ar2는 서로 동일하거나 상이하며, 각각 독립적으로 C1~C40의 알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택될 수 있다. 더욱 바람직하게는, 상기 Ar1은 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기일 수 있고, 상기 Ar2는 C6~C60의 아릴기일 수 있다. 이때, 상기 Ar1이 헤테로아릴기이고, Ar2가 아릴기일 경우에는 'Ar1이 아릴기이고, Ar2가 헤테로아릴기인 경우' 또는 'Ar1 및 Ar2 모두 C6~C60의 헤테로아릴기인 경우'에 비해 밴드갭이 더 감소할 수 있다. 이러한 화합물은 유기 전계 발광 소자의 발광층 재료로 사용될 수 있으며, 바람직하게는, 적색의 인광 호스트 재료로 사용될 수 있다.Preferably, Ar 1 and Ar 2 are the same or different and each independently represents a C 1 to C 40 alkyl group, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, and C 6 To C 60 arylamine groups. More preferably, Ar 1 may be a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms, and Ar 2 may be a C 6 to C 60 aryl group. When Ar 1 is a heteroaryl group and Ar 2 is an aryl group, when Ar 1 is an aryl group and Ar 2 is a heteroaryl group, or both Ar 1 and Ar 2 are C 6 to C 60 heteroaryl The bandgap can be further reduced compared to the case of ' Such a compound can be used as a light emitting layer material of an organic electroluminescent device, and can be preferably used as a red phosphorescent host material.

m은 0 내지 3의 정수이다. 이때, m이 0일 경우에는 수소가 치환기 R2로 치환되지 않은 것을 의미한다. m이 1 내지 3의 정수일 경우에는 수소가 치환기 R2로 치환된 것을 의미하며, R2는 서로 동일하거나 상이하며, 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된다.and m is an integer of 0 to 3. In this case, when m is 0, it means that hydrogen is not substituted with substituent R 2 . when m is an integer of 1 to 3, it means that the substituent is hydrogen substituted with R 2, and R 2 are the same or different, each independently represent a deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C A C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocyclic cycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group , A heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group of the group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C 60 aryl boron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 of the And an arylamine group.

R3 및 R4는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있다.R 3 and R 4 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ alkenyl group of the C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C group of 60 arylboronic, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ selected from the group consisting of an aryl amine of the C 60 of or, or adjacent groups bonded fused to the A ring can be formed.

바람직하게는, 상기 R3 및 R4는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있다. Preferably, R 3 and R 4 are the same or different from each other and each independently represents hydrogen, deuterium (D), halogen, cyano, nitro, C 1 to C 40 alkyl, C 6 to C 60 aryl group, a number of nuclear atoms of 5 to 60 heteroaryl group, and a C 6 ~, or selected from the group consisting of an aryl amine of the C 60 of, or adjacent groups combine to form a condensed ring.

상기 L1 및 L2의 아릴렌기 및 헤테로아릴렌기와, 상기 Ar1 및 Ar2, R1 내지 R4의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.Wherein L 1, and arylene group of L 2 and a heteroarylene group, an alkyl group of said Ar 1 and Ar 2, R 1 to R 4, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, An alkyl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, A nitro group, a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C An aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 ~ C 60 aryl silyl group, C 1 ~ C 40 alkyl boron group, C 6 ~ C of the group 60 arylboronic of, C 6 ~ C 60 aryl phosphine group, C 6 ~ aryl phosphine oxide of the C 60 group And C 6 -C An arylamine group having 1 to 60 carbon atoms, and when the substituent is plural, they may be the same or different from each other.

이러한 화학식 1로 표시되는 화합물은 하기 화학식 3 내지 5 중에서 적어도 어느 하나로 구체화될 수 있다. 그러나, 이에 특별히 한정되지 않는다.The compound represented by the formula (1) may be embodied as at least one of the following formulas (3) to (5). However, it is not particularly limited.

[화학식 3](3)

Figure pat00008
Figure pat00008

[화학식 4][Chemical Formula 4]

Figure pat00009
Figure pat00009

[화학식 5][Chemical Formula 5]

Figure pat00010
Figure pat00010

상기 화학식 3 내지 5에서, L1, L2, Ar1, Ar2, m, R2는 각각 상기 화학식 1에서 정의한 바와 같다.Wherein L 1 , L 2 , Ar 1 , Ar 2 , m and R 2 are the same as defined in the above formula (1).

또한, 이러한 화학식 1로 표시되는 화합물은 하기 화학식 6 내지 8 중에서 적어도 어느 하나로 보다 구체화될 수 있다. 그러나, 이에 특별히 한정되지 않는다.Further, the compound represented by the formula (1) may be further formulated into at least one of the following formulas (6) to (8). However, it is not particularly limited.

[화학식 6][Chemical Formula 6]

Figure pat00011
Figure pat00011

[화학식 7](7)

Figure pat00012
Figure pat00012

[화학식 8][Chemical Formula 8]

Figure pat00013
Figure pat00013

상기 화학식 6 내지 8에서, L1, L2, Ar1, Ar2, m, R2는 각각 상기 화학식 1에서 정의한 바와 같다.In Formula 6 to 8, L 1 , L 2 , Ar 1 , Ar 2 , m and R 2 are as defined in Formula 1, respectively.

본 발명의 바람직한 일례에 따르면, 상기 Ar1은 하기 화학식 9로 표시되는 치환체일 수 있다. According to a preferred embodiment of the present invention, Ar 1 may be a substituent represented by the following general formula (9).

[화학식 9][Chemical Formula 9]

Figure pat00014
Figure pat00014

상기 화학식 9에서, *는 상기 화학식 1에 결합되는 부분을 의미한다.In the above formula (9), * denotes a moiety bonded to the formula (1).

Z1 내지 Z5는 서로 동일하거나 상이하며, 각각 독립적으로 N 또는 C(R5)이고, 이때 상기 R5이 복수인 경우, 이들은 서로 동일하거나 상이하다.Z 1 to Z 5 are the same as or different from each other and each independently N or C (R 5 ), wherein when R 5 is plural, they are the same as or different from each other.

R5는 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있다.R 5 is hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 3 ~ C 40 of the A cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, an aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 An aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, a C 6 to C 60 An arylphosphine group, an arylphosphine oxide group having 6 to 60 carbon atoms, and an arylamine group having 6 to 60 carbon atoms, or may be bonded to an adjacent group to form a condensed ring.

상기 R5의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.Alkyl groups of the R 5, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkyl boron group, an aryl boron group, an aryl phosphine group, aryl phosphine oxide group and an arylamine group each independently a heavy hydrogen (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C A C 3 to C 40 cycloalkyl group, a heterocyclic cycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkenyl group, C 6 -C 60 aryloxy groups, C 1 -C 40 alkylsilyl groups, C 6 -C 60 arylsilyl groups, C 1 -C 40 alkylboron groups, C 6 -C 60 the arylboronic group, C 6 ~ C 60 aryl phosphine group, substituted with one or more substituents selected from the group consisting of an aryl amine of the C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 of And when the substituent is plural, they may be the same or different from each other.

상기 화학식 9로 표시되는 치환체는 하기 A-1 내지 A-15 중 어느 하나로 보다 구체화될 수 있다. 그러나, 이에 특별히 한정되지 않는다.The substituent represented by the above formula (9) may be further formulated by any one of the following A-1 to A-15. However, it is not particularly limited.

Figure pat00015
Figure pat00015

상기 A-1 내지 A-15 에서, R5는 상기 화학식 9에서 정의한 바와 같다.In the above A-1 to A-15, R < 5 >

p는 0 내지 4의 정수이다. 상기 p가 0일 경우, 수소가 치환기 R6으로 치환되지 않은 것을 의미한다. 상기 p가 1 내지 4의 정수일 경우, R6은 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, 상기 R6이 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.p is an integer of 0 to 4; When p is 0, it means that hydrogen is not substituted with substituent R 6 . If the p is 1 to 4 integer, R 6 is deuterium (D), a halogen, cyano group, nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 of the alkynyl group, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 hetero cycloalkyl, heteroaryl of C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 aryl group, C 1 ~ C 40 alkyloxy A C 6 to C 60 aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ selected from the group consisting of an aryl amine of the C 60 or, or the group bonded adjacent to form a condensed ring And when R < 6 > is plural, they may be the same or different from each other.

상기 R6의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.Alkyl group of the R 6, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkyl boron group, an aryl boron group, an aryl phosphine group, aryl phosphine oxide group and an arylamine group each independently a heavy hydrogen (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C A C 3 to C 40 cycloalkyl group, a heterocyclic cycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkenyl group, C 6 -C 60 aryloxy groups, C 1 -C 40 alkylsilyl groups, C 6 -C 60 arylsilyl groups, C 1 -C 40 alkylboron groups, C 6 -C 60 the arylboronic group, C 6 ~ C 60 aryl phosphine group, substituted with one or more substituents selected from the group consisting of an aryl amine of the C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 of And when the substituent is plural, they may be the same or different from each other.

이상에서 설명한 본 발명의 화학식 1로 표시되는 화합물은 하기 예시되는 화합물 1 내지 576 중 어느 하나로 표시되는 화합물로 보다 구체화될 수 있다. 그러나, 본 발명의 화학식 1로 표시되는 화합물이 하기 예시된 것들에 의해 한정되는 것은 아니다.The compound represented by the formula (1) of the present invention described above can be further represented by a compound represented by any one of the following compounds 1 to 576. However, the compounds represented by formula (1) of the present invention are not limited by the following examples.

Figure pat00016
Figure pat00016

Figure pat00017
Figure pat00017

Figure pat00018
Figure pat00018

Figure pat00019
Figure pat00019

Figure pat00020
Figure pat00020

Figure pat00021
Figure pat00021

Figure pat00022
Figure pat00022

Figure pat00023
Figure pat00023

Figure pat00024
Figure pat00024

Figure pat00025
Figure pat00025

Figure pat00026
Figure pat00026

Figure pat00027
Figure pat00027

Figure pat00028
Figure pat00028

Figure pat00029
Figure pat00029

Figure pat00030
Figure pat00030

Figure pat00031
Figure pat00031

Figure pat00032
Figure pat00032

Figure pat00033
Figure pat00033

Figure pat00034
Figure pat00034

Figure pat00035
Figure pat00035

Figure pat00036
Figure pat00036

Figure pat00037
Figure pat00037

Figure pat00038
Figure pat00038

Figure pat00039
Figure pat00039

Figure pat00040
Figure pat00040

Figure pat00041
Figure pat00041

Figure pat00042
Figure pat00042

Figure pat00043
Figure pat00043

Figure pat00044
Figure pat00044

Figure pat00045
Figure pat00045

Figure pat00046
Figure pat00046

Figure pat00047
Figure pat00047

Figure pat00048
Figure pat00048

Figure pat00049
Figure pat00049

Figure pat00050
Figure pat00050

Figure pat00051
Figure pat00051

Figure pat00052
Figure pat00052

Figure pat00053
Figure pat00053

Figure pat00054
Figure pat00054

Figure pat00055
Figure pat00055

Figure pat00056
Figure pat00056

Figure pat00057
Figure pat00057

Figure pat00058
Figure pat00058

Figure pat00059
Figure pat00059

Figure pat00060
Figure pat00060

Figure pat00061
Figure pat00061

Figure pat00062
Figure pat00062

Figure pat00063
Figure pat00063

본 발명에서 “알킬”은 탄소수 1 내지 40의 직쇄 또는 측쇄의 포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이러한 알킬의 예로는 메틸, 에틸, 프로필, 이소부틸, sec-부틸, 펜틸, iso-아밀, 헥실 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, " alkyl " means a monovalent substituent derived from a linear or branched saturated hydrocarbon having 1 to 40 carbon atoms. Examples of such alkyl include, but are not limited to, methyl, ethyl, propyl, isobutyl, sec-butyl, pentyl, iso-amyl and hexyl.

본 발명에서 “알케닐(alkenyl)”은 탄소-탄소 이중 결합을 1개 이상 가진탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이러한 알케닐의 예로는 비닐(vinyl), 알릴(allyl), 이소프로펜일(isopropenyl), 2-부텐일(2-butenyl) 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "alkenyl" means a monovalent substituent derived from a straight-chain or branched-chain unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon double bond. Examples of such alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, 2-butenyl, and the like.

본 발명에서“알키닐(alkynyl)”은 탄소-탄소 삼중 결합을 1개 이상 가진탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이러한 알키닐의 예로는 에티닐(ethynyl), 2-프로파닐(2-propynyl) 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, " alkynyl " means a monovalent substituent derived from a straight-chain or branched-chain unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon triple bond. Examples of such alkynyls include, but are not limited to, ethynyl, 2-propynyl, and the like.

본 발명에서 “아릴”은 단독 고리 또는 2 이상의 고리가 조합된 탄소수 6 내지 60의 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있다. 이러한 아릴의 예로는 페닐, 나프틸, 페난트릴, 안트릴 등을 들 수 있으나, 이에 한정되지는 않는다.&Quot; Aryl " in the present invention means a monovalent substituent derived from an aromatic hydrocarbon having 6 to 60 carbon atoms in which a single ring or two or more rings are combined. Also, a form in which two or more rings are pendant or condensed with each other may be included. Examples of such aryl include, but are not limited to, phenyl, naphthyl, phenanthryl, anthryl, and the like.

본 발명에서 “헤테로아릴”은 핵원자수 5 내지 60의 모노헤테로사이클릭 또는 폴리헤테로사이클릭 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이때, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로원자로 치환된다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있고, 나아가 아릴기와의 축합된 형태도 포함될 수 있다. 이러한 헤테로아릴의 예로는 피리딜, 피라지닐, 피리미디닐, 피리다지닐, 트리아지닐과 같은 6-원 모노사이클릭 고리, 페녹사티에닐(phenoxathienyl), 인돌리지닐(indolizinyl), 인돌릴(indolyl), 퓨리닐(purinyl), 퀴놀릴(quinolyl), 벤조티아졸(benzothiazole), 카바졸릴(carbazolyl)과 같은 폴리사이클릭 고리 및 2-퓨라닐, N-이미다졸릴, 2-이속사졸릴, 2-피리디닐, 2-피리미디닐 등을 들 수 있으나, 이에 한정되지는 않는다.&Quot; Heteroaryl " in the present invention means a monovalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon having 5 to 60 nuclear atoms. Wherein at least one of the carbons, preferably one to three carbons, is replaced by a heteroatom such as N, O, S or Se. In addition, a form in which two or more rings are pendant or condensed with each other may be included, and further, a condensed form with an aryl group may be included. Examples of such heteroaryls include 6-membered monocyclic rings such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, phenoxathienyl, indolizinyl, indolyl indolyl), purinyl, quinolyl, benzothiazole, carbazolyl, and heterocyclic rings such as 2-furanyl, N-imidazolyl, 2- , 2-pyridinyl, 2-pyrimidinyl, and the like, but are not limited thereto.

본 발명에서 “아릴옥시”는 RO-로 표시되는 1가의 치환기로, 상기 R은 탄소수 6 내지 60의 아릴을 의미한다. 이러한 아릴옥시의 예로는 페닐옥시, 나프틸옥시, 디페닐옥시 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "aryloxy" is a monovalent substituent represented by RO-, and R represents aryl having 6 to 60 carbon atoms. Examples of such aryloxy include, but are not limited to, phenyloxy, naphthyloxy, diphenyloxy, and the like.

본 발명에서 “알킬옥시”는 R’O-로 표시되는 1가의 치환기로, 상기 R’는 탄소수 1 내지 40의 알킬을 의미한다. 이러한 알킬옥시는 직쇄(linear), 측쇄(branched) 또는 사이클릭(cyclic) 구조를 포함할 수 있다. 이러한 알킬옥시의 예로는 메톡시, 에톡시, n-프로폭시, 1-프로폭시, t-부톡시, n-부톡시, 펜톡시 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, " alkyloxy " means a monovalent substituent group represented by R'O-, and R 'means alkyl having 1 to 40 carbon atoms. Such alkyloxy may include linear, branched or cyclic structures. Examples of such alkyloxy include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-propoxy, t-butoxy, n-butoxy and pentoxy.

본 발명에서 “아릴아민”은 탄소수 6 내지 60의 아릴로 치환된 아민을 의미한다.&Quot; Arylamine " in the present invention means an amine substituted with aryl having 6 to 60 carbon atoms.

본 발명에서 “시클로알킬”은 탄소수 3 내지 40의 모노사이클릭 또는 폴리사이클릭 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이러한 사이클로알킬의 예로는 사이클로프로필, 사이클로펜틸, 사이클로헥실, 노르보닐(norbornyl), 아다만틴(adamantine) 등을 들 수 있으나, 이에 한정되지는 않는다.&Quot; Cycloalkyl " in the present invention means a monovalent substituent derived from a monocyclic or polycyclic non-aromatic hydrocarbon having 3 to 40 carbon atoms. Examples of such cycloalkyls include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, adamantine, and the like.

본 발명에서 “헤테로시클로알킬”은 핵원자수 3 내지 40의 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미하며, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로 원자로 치환된다. 이러한 헤테로시클로알킬의 예로는 모르폴린, 피페라진 등을 들 수 있으나, 이에 한정되지는 않는다.&Quot; Heterocycloalkyl " in the present invention means a monovalent substituent derived from a non-aromatic hydrocarbon having 3 to 40 nuclear atoms, wherein at least one of the carbons, preferably one to three carbons, Or < RTI ID = 0.0 > Se. ≪ / RTI > Examples of such heterocycloalkyl include, but are not limited to, morpholine, piperazine, and the like.

본 발명에서 “알킬실릴”은 탄소수 1 내지 40의 알킬로 치환된 실릴이고, “아릴실릴”은 탄소수 6 내지 60의 아릴로 치환된 실릴을 의미한다.In the present invention, "alkylsilyl" is silyl substituted with alkyl having 1 to 40 carbon atoms, and "arylsilyl" means silyl substituted with aryl having 6 to 60 carbon atoms.

본 발명에서 “알킬보론”은 탄소수 1 내지 40의 알킬로 치환된 보론이고, “아릴보론”은 탄소수 6 내지 60의 아릴로 치환된 보론을 의미한다.In the present invention, "alkyl boron" is boron substituted with alkyl having 1 to 40 carbon atoms, and "aryl boron" means boron substituted with aryl having 6 to 60 carbon atoms.

본 발명에서 "아릴포스핀"은 탄소수 6 내지 60의 아릴로 치환된 포스핀을 의미하고, "아릴포스핀옥사이드기"는 탄소수 6 내지 60의 아릴로 치환된 포스핀이 O를 포함하는 것을 의미한다.In the present invention, "arylphosphine" means a phosphine substituted with aryl having 6 to 60 carbon atoms, and "arylphosphine oxide group" means that phosphine substituted with aryl having 6 to 60 carbon atoms includes O do.

본 발명에서 “축합고리”는 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리, 축합 헤테로방향족 고리 또는 이들의 조합된 형태를 의미한다.In the present invention, the term "condensed rings" means condensed aliphatic rings, condensed aromatic rings, condensed heteroaliphatic rings, condensed heteroaromatic rings, or a combination thereof.

이와 같은 본 발명의 화학식 1로 표시되는 화합물은 하기 실시예의 합성과정을 참고하여 다양하게 합성할 수 있다.The compound represented by formula (1) of the present invention can be synthesized in various ways with reference to the synthesis process of the following examples.

2. 유기 2. Organic 전계Field 발광 소자 Light emitting element

본 발명은 상기 화학식 1로 표시되는 화합물을 포함하는 유기 전계 발광 소자를 제공한다.The present invention provides an organic electroluminescent device comprising a compound represented by the above formula (1).

보다 구체적으로, 본 발명에 따른 유기 전계 발광 소자는 양극(anode), 음극(cathode) 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며, 상기 1층 이상의 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함한다. 이때, 상기 화합물은 단독으로 사용되거나, 또는 2 이상이 혼합되어 사용될 수 있다.More specifically, the organic electroluminescent device according to the present invention includes at least one anode, an anode, and at least one organic layer sandwiched between the anode and the cathode, and at least one of the one or more organic layers Include the compounds represented by the above formula (1). At this time, the compounds may be used alone or in combination of two or more.

상기 1층 이상의 유기물층은 정공 주입층, 정공 수송층, 발광 보조층, 발광층, 전자 수송층 및 전자 주입층 중 어느 하나 이상일 수 있고, 이 중에서 적어도 하나의 유기물층은 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 구체적으로, 상기 화학식 1의 화합물을 포함하는 유기물층은 발광층인 것이 바람직하다.The at least one organic material layer may include at least one of a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer, and an electron injecting layer. have. Specifically, the organic compound layer containing the compound of Formula 1 is preferably a light emitting layer.

본 발명의 유기 전계 발광 소자의 발광층은 호스트 재료(바람직하게는, 인광 호스트 재료)를 포함할 수 있다. 또한, 본 발명의 유기 전계 발광 소자의 발광층은 상기 화학식 1의 화합물 이외의 화합물을 호스트로 포함할 수 있다.The light emitting layer of the organic electroluminescence device of the present invention may include a host material (preferably, a phosphorescent host material). The light emitting layer of the organic electroluminescent device of the present invention may contain a compound other than the compound of Formula 1 as a host.

이러한 본 발명의 유기 전계 발광 소자의 구조는 특별히 한정되지 않으나, 비제한적인 예로 기판, 양극, 정공 주입층, 정공 수송층, 발광 보조층, 발광층, 전자 수송층 및 음극이 순차적으로 적층된 구조일 수 있다. 이때, 상기 정공 주입층, 정공 수송층, 발광 보조층, 발광층, 전자 수송층 및 전자 주입층 중 하나 이상은 상기 화학식 1로 표시되는 화합물을 포함할 수 있고, 바람직하게는 발광층이 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 여기서, 상기 전자 수송층 위에는 전자 주입층이 추가로 적층될 수 있다. 또한, 본 발명의 유기 전계 발광 소자의 구조는 전극과 유기물층 계면에 절연층 또는 접착층이 삽입된 구조일 수 있다.The structure of the organic electroluminescent device of the present invention is not particularly limited, but may be a structure in which a substrate, an anode, a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer and a cathode are sequentially stacked . At least one of the hole injecting layer, the hole transporting layer, the light-emitting auxiliary layer, the light emitting layer, the electron transporting layer, and the electron injecting layer may include the compound represented by Formula 1, ≪ / RTI > compounds. Here, an electron injection layer may be further stacked on the electron transport layer. Further, the structure of the organic electroluminescent device of the present invention may be a structure in which an insulating layer or an adhesive layer is inserted into the interface between the electrode and the organic layer.

한편, 본 발명의 유기 전계 발광 소자는 상기 유기물층 중 1층 이상이 상기 화학식 1로 표시되는 화합물을 포함하는 것을 제외하고는, 당업계에 공지된 재료 및 방법으로 유기물층 및 전극을 형성하여 제조할 수 있다.Meanwhile, the organic electroluminescent device of the present invention can be manufactured by forming an organic material layer and an electrode by materials and methods known in the art, except that at least one of the organic material layers includes the compound represented by the above formula have.

상기 유기물층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포법의 예로는 스핀 코팅, 딥코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이에 한정되지는 않는다.The organic material layer may be formed by a vacuum deposition method or a solution coating method. Examples of the solution coating method include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.

본 발명의 유기 전계 발광 소자 제조시 사용되는 기판은 특별히 한정되지 않으나, 실리콘 웨이퍼, 석영, 유리판, 금속판, 플라스틱 필름 및 시트 등을 사용할 수 있다.The substrate used in the fabrication of the organic electroluminescent device of the present invention is not particularly limited, but silicon wafer, quartz, glass plate, metal plate, plastic film and sheet can be used.

또한, 양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 또는 폴리아닐린과 같은 전도성 고분자; 및 카본블랙 등을 들 수 있으나, 이에 한정되지는 않는다.Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); A combination of a metal and an oxide such as ZnO: Al or SnO2: Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole or polyaniline; And carbon black, but are not limited thereto.

또한, 음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석, 또는 납과 같은 금속 또는 이들의 합금; 및 LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등을 들 수 있으나, 이에 한정되지는 않는다.Examples of the negative electrode material include metals such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or alloys thereof; And multi-layer structure materials such as LiF / Al or LiO2 / Al, but are not limited thereto.

또한, 정공 주입층, 정공 수송층, 전자 주입층 및 전자 수송층은 특별히 한정되는 것은 아니며, 당 업계에 알려진 통상의 물질을 사용할 수 있다.The hole injecting layer, the hole transporting layer, the electron injecting layer and the electron transporting layer are not particularly limited, and ordinary materials known in the art can be used.

이하, 본 발명을 실시예를 통하여 상세히 설명하면 다음과 같다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.

[[ 준비예Preparation Example 1] Core1] Core 1 의1 of 합성 synthesis

Figure pat00064
Figure pat00064

질소 기류 하에서 10-bromo-7H-benzo[c]carbazole (50 g, 168.82 mmol), (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid (55.58 g, 168.82 mmol), Pd(PPh3)4 (9.76 g, 5 mol%), NaOH (20.26 g, 506.47 mmol)을 THF/H2O (400 ml/100 ml)에 넣고 80에서 12시간 동안 교반하였다. 반응 종결 후 메틸렌클로라이드로 추출하고 MgSO4를 넣고 필터하였다. 필터된 유기층의 용매를 제거한 후 컬럼크로마토그래피를 이용하여 목적 화합물인 Core 1 (72.7 g, 수율 86 %)을 획득하였다. (50 g, 168.82 mmol), (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl) boronic acid (55.58 g, 168.82 mmol) mmol), Pd (PPh 3) 4 (9.76 g, 5 mol%) , NaOH (20.26 g, 506.47 mmol) were dissolved in THF / H 2 O (400 ml / 100 ml) was stirred at 80 for 12 hours. After completion of the reaction, the reaction mixture was extracted with methylene chloride, and the mixture was filtered with MgSO 4 . After removing the solvent of the filtered organic layer, Core 1 (72.7 g, yield 86%) was obtained by column chromatography.

1H-NMR: δ 1.68 (s, 6H), 7.14 (m, 9H), 7.33 (d, 1H), 7.69 (m, 5H), 7.74 (m, 2H), 7.86 (s, 1H), 7.95 (d, 2H), 8.52 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 1.68 ( s, 6H), 7.14 (m, 9H), 7.33 (d, 1H), 7.69 (m, 5H), 7.74 (m, 2H), 7.86 (s, 1H), 7.95 ( d, 2H), 8.52 (d, 1H), 11.63 (s, 1H)

[[ 준비예Preparation Example 2] Core2] Core 2 의2 of 합성 synthesis

Figure pat00065
Figure pat00065

(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid 대신 (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-3-yl)boronic acid (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 2 (69.3 g, 수율 82 %)을 얻었다.(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-3-yl) boronic acid was used instead of (9,9-dimethyl-10-phenyl-9,10-dihydroacridin- , 168.82 mmol) was used as a starting material, to obtain Core 2 (69.3 g, yield 82%).

1H-NMR: δ 1.68 (s, 6H), 7.11 (m, 12H), 7.62 (m, 4H), 7.74 (d, 1H), 7.85 (s, 1H), 7.97 (d, 2H), 8.56 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 1.68 ( s, 6H), 7.11 (m, 12H), 7.62 (m, 4H), 7.74 (d, 1H), 7.85 (s, 1H), 7.97 (d, 2H), 8.56 ( d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 3] Core3] Core 3 의3 of 합성 synthesis

Figure pat00066
Figure pat00066

(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid 대신 (10-phenyl-10H-phenoxazin-3-yl)boronic acid (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 3 (67.3 g, 수율 84 %)을 얻었다.Phenyl-10H-phenoxazin-3-yl) boronic acid (51.2 g, 168.8 mmol) was used instead of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- , Core 3 (67.3 g, yield 84%) was obtained in the same manner as in Preparation Example 1, except that

1H-NMR: δ 7.19 (m, 12H), 7.58 (m, 4H), 7.76 (d, 1H), 7.85 (s, 1H), 8.01 (d, 2H), 8.56 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.19 (m, 12H), 7.58 (m, 4H), 7.76 (d, s, 1 H)

[[ 준비예Preparation Example 4] Core4] Core 4 의4 of 합성 synthesis

Figure pat00067
Figure pat00067

(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid 대신 (10-phenyl-10H-phenoxazin-2-yl)boronic acid (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 4 (63.3 g, 수율 79 %)을 얻었다.Phenyl-10H-phenoxazin-2-yl) boronic acid (51.2 g, 168.8 mmol) instead of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- , Core 4 (63.3 g, yield 79%) was obtained in the same manner as in Preparation Example 1, except that

1H-NMR: δ 7.17 (m, 12H), 7.57 (m, 4H), 7.74 (d, 1H), 7.86 (s, 1H), 8.01 (d, 2H), 8.55 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.17 (m, 12H), 7.57 (m, 4H), 7.74 (d, s, 1 H)

[[ 준비예Preparation Example 5] Core5] Core 5 의5 of 합성 synthesis

Figure pat00068
Figure pat00068

(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid 대신 (10-phenyl-10H-phenothiazin-3-yl)boronic acid (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 5 (68.7 g, 수율 83 %)을 얻었다.Phenyl-10H-phenothiazin-3-yl) boronic acid (53.9 g, 168.8 mmol) was used in place of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- , Core 5 (68.7 g, yield 83%) was obtained in the same manner as in Preparation Example 1, except that

1H-NMR: δ 7.18 (m, 12H), 7.58 (m, 4H), 7.75 (d, 1H), 7.98 (d, 2H), 8.53 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.18 (m, 12H), 7.58 (m, 4H), 7.75 (d,

[[ 준비예Preparation Example 6] Core6] Core 6 의6 of 합성 synthesis

Figure pat00069
Figure pat00069

(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)boronic acid 대신 (10-phenyl-10H-phenothiazin-2-yl)boronic acid (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 6 (67.1 g, 수율 81 %)을 얻었다.10-phenyl-10H-phenothiazin-2-yl) boronic acid (53.9 g, 168.8 mmol) was used instead of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- , Core 6 (67.1 g, yield 81%) was obtained in the same manner as in Preparation Example 1, except that

1H-NMR: δ 7.13 (m, 11H), 7.34 (d, 1H), 7.57 (m, 4H), 7.78 (d, 1H), 7.85 (s, 1H), 7.97 (d, 2H), 8.52 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 7.13 ( m, 11H), 7.34 (d, 1H), 7.57 (m, 4H), 7.78 (d, 1H), 7.85 (s, 1H), 7.97 (d, 2H), 8.52 ( d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 7] Core7] Core 7 의7's 합성 synthesis

Figure pat00070
Figure pat00070

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (55.58 g, 168.82mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 7 (69.3 g, 수율 82 %)을 얻었다.The procedure of Preparation Example 1 was repeated except that 9-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used in place of 10-bromo-7H- g, yield: 82%).

1H-NMR: δ 1.68 (s, 6H), 7.17 (m, 9H), 7.35 (d, 1H), 7.57 (m, 5H), 7.75 (s, 2H), 7.95 (d, 2H), 8.34 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 1.68 ( s, 6H), 7.17 (m, 9H), 7.35 (d, 1H), 7.57 (m, 5H), 7.75 (s, 2H), 7.95 (d, 2H), 8.34 ( d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 8] Core8] Core 8 의8 of 합성 synthesis

Figure pat00071
Figure pat00071

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 2와 동일한 과정을 수행하여 Core 8 (65.9 g, 수율 78 %)을 얻었다.The procedure of Preparation Example 2 was repeated except that 9-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used instead of 10-bromo-7H- g, yield 78%).

1H-NMR: δ 1.68 (s, 6H), 7.18 (m, 12H), 7.57 (m, 4H), 7.72 (s, 1H), 7.99 (d, 2H), 8.30 (d, 1H), 8.55 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 1.68 (s, 6H), 7.18 (m, 12H), 7.57 (m, 4H), 7.72 d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 9] Core9] Core 9 의9 of 합성 synthesis

Figure pat00072
Figure pat00072

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 3과 동일한 과정을 수행하여 Core 9 (64.1 g, 수율 80 %)을 얻었다.The procedure of Preparation Example 3 was repeated except that 9-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used instead of 10-bromo- g, yield: 80%).

1H-NMR: δ 7.19 (m, 12H), 7.55 (m, 4H), 7.96 (d, 2H), 8.29 (d, 1H), 8.57 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.19 (m, 12H), 7.55 (m, 4H), 7.96 (d, 2H), 8.29

[[ 준비예Preparation Example 10] Core10] Core 10 의Ten 합성 synthesis

Figure pat00073
Figure pat00073

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 4과 동일한 과정을 수행하여 Core 10 (60.9 g, 수율 76 %)을 얻었다.The procedure of Preparation Example 4 was repeated except that 9-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used in place of 10-bromo-7H- g, yield: 76%).

1H-NMR: δ 7.21 (m, 12H), 7.57 (m, 4H), 7.72 (s, 1H), 7.96 (d, 2H), 8.30 (d, 1H), 8.55 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.21 (m, 12H), 7.57 (m, 4H), 7.72 (s, s, 1 H)

[[ 준비예Preparation Example 11] Core11] Core 11 의Eleven 합성 synthesis

Figure pat00074
Figure pat00074

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 5와 동일한 과정을 수행하여 Core 11 (67.1 g, 수율 81 %)을 얻었다.The procedure of Preparation Example 5 was repeated except that 9-bromo-7H-benzo [c] carbazole (53.9 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield: 81%).

1H-NMR: δ 7.29 (m, 12H), 7.57 (m, 4H), 7.72 (s, 1H), 7.94 (d, 2H), 8.29 (d, 1H), 8.55 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.29 (m, 12H), 7.57 (m, 4H), 7.72 (s, s, 1 H)

[[ 준비예Preparation Example 12] Core12] Core 12 의12 of 합성 synthesis

Figure pat00075
Figure pat00075

10-bromo-7H-benzo[c]carbazole 대신 9-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 6과 동일한 과정을 수행하여 Core 12 (63.8 g, 수율 77 %)을 얻었다.The procedure of Preparation Example 6 was repeated except that 9-bromo-7H-benzo [c] carbazole (53.9 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield: 77%).

1H-NMR: δ 7.17 (m, 11H), 7.37 (d, 1H), 7.57 (m, 4H), 7.79 (s, 1H), 8.01 (d, 2H), 8.34 (d, 1H), 8.57 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 7.17 ( m, 11H), 7.37 (d, 1H), 7.57 (m, 4H), 7.79 (s, 1H), 8.01 (d, 2H), 8.34 (d, 1H), 8.57 ( d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 13] Core13] Core 13 의Thirteen 합성 synthesis

Figure pat00076
Figure pat00076

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 13 (60.6 g, 수율 72 %)을 얻었다.The procedure of Preparation Example 1 was repeated except that 8-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used in place of 10-bromo-7H- g, yield: 72%).

1H-NMR: δ 1.68 (s, 6H), 7.13 (m, 9H), 7.34 (d, 1H), 7.52 (m, 6H), 7.79 (s, 1H), 8.01 (d, 2H), 8.27 (d, 1H), 8.53 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 1.68 ( s, 6H), 7.13 (m, 9H), 7.34 (d, 1H), 7.52 (m, 6H), 7.79 (s, 1H), 8.01 (d, 2H), 8.27 ( d, 1 H), 8.53 (d, 1 H), 11.63 (s, 1 H)

[[ 준비예Preparation Example 14] Core14] Core 14 의14 of 합성 synthesis

Figure pat00077
Figure pat00077

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 2와 동일한 과정을 수행하여 Core 14 (57.5 g, 수율 68 %)을 얻었다.The procedure of Preparation Example 2 was repeated except that 8-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used in place of 10-bromo-7H- g, yield 68%).

1H-NMR: δ 7.17 (m, 12H), 7.56 (m, 5H), 8.03 (d, 2H), 8.27 (d, 1H), 8.53 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.17 (m, 12H), 7.56 (m, 5H), 8.03 (d, 2H), 8.27

[[ 준비예Preparation Example 15] Core15] Core 15 의Fifteen 합성 synthesis

Figure pat00078
Figure pat00078

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 3과 동일한 과정을 수행하여 Core 15 (56.1 g, 수율 70 %)을 얻었다.The procedure of Preparation Example 3 was repeated except that 8-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield 70%).

1H-NMR: δ 7.17 (m, 12H), 7.57 (m, 5H), 8.02 (d, 2H), 8.28 (d, 1H), 8.53 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.17 (m, 12H), 7.57 (m, 5H), 8.02 (d, 2H), 8.28

[[ 준비예Preparation Example 16] Core16] Core 16 의16 합성 synthesis

Figure pat00079
Figure pat00079

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 4와 동일한 과정을 수행하여 Core 16 (52.8 g, 수율 66 %)을 얻었다.The procedure of Preparation Example 4 was repeated except that 8-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield 66%).

1H-NMR: δ 7.18 (m, 12H), 7.54 (m, 5H), 8.02 (d, 2H), 8.28 (d, 1H), 8.53 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.18 (m, 12H), 7.54 (m, 5H), 8.02 (d, 2H), 8.28

[[ 준비예Preparation Example 17] Core17] Core 17 의17 합성 synthesis

Figure pat00080
Figure pat00080

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 5와 동일한 과정을 수행하여 Core 17 (57.2 g, 수율 69 %)을 얻었다.The procedure of Preparation Example 5 was repeated except that 8-bromo-7H-benzo [c] carbazole (53.9 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield 69%).

1H-NMR: δ 7.43 (m, 17H), 8.07 (d, 2H), 8.27 (d, 1H), 8.59 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.43 (m, 17H), 8.07 (d, 2H), 8.27 (d,

[[ 준비예Preparation Example 18] Core18] Core 18 의18 합성 synthesis

Figure pat00081
Figure pat00081

10-bromo-7H-benzo[c]carbazole 대신 8-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 6과 동일한 과정을 수행하여 Core 18 (52.2 g, 수율 63 %)을 얻었다.The procedure of Preparation Example 6 was repeated except that 8-bromo-7H-benzo [c] carbazole (53.9 g, 168.8 mmol) was used in place of 10-bromo-7H- g, yield: 63%).

1H-NMR: δ 7.21 (m, 11H), 7.37 (d, 1H), 7.52 (m, 5H), 8.03 (d, 2H), 8.23 (d, 1H), 8.55 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 7.21 ( m, 11H), 7.37 (d, 1H), 7.52 (m, 5H), 8.03 (d, 2H), 8.23 (d, 1H), 8.55 (d, 1H), 11.63 ( s, 1 H)

[[ 준비예Preparation Example 19] Core19] Core 19 의19's 합성 synthesis

Figure pat00082
Figure pat00082

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 1과 동일한 과정을 수행하여 Core 19 (62.6 g, 수율 74 %)을 얻었다.The procedure of Preparation Example 1 was repeated except that 11-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used in place of 10-bromo-7H- g, yield: 74%).

1H-NMR: δ 1.68 (s, 6H), 7.11 (m, 9H), 7.37 (d, 1H), 7.52 (m, 8H), 7.94 (d, 2H), 8.32 (d, 1H), 11.63 (s, 1H) 1 H-NMR: δ 1.68 ( s, 6H), 7.11 (m, 9H), 7.37 (d, 1H), 7.52 (m, 8H), 7.94 (d, 2H), 8.32 (d, 1H), 11.63 ( s, 1 H)

[[ 준비예Preparation Example 20] Core20] Core 20 의Twenty 합성 synthesis

Figure pat00083
Figure pat00083

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (55.58 g, 168.82 mmol)을 사용하는 것을 제외하고는 준비예 2와 동일한 과정을 수행하여 Core 20 (58.3 g, 수율 69 %)을 얻었다.The procedure of Preparation Example 2 was repeated except that 11-bromo-7H-benzo [c] carbazole (55.58 g, 168.82 mmol) was used in place of 10-bromo-7H- g, yield 69%).

1H-NMR: δ 1.68 (s, 6H), 7.11 (m, 9H), 7.36 (d, 1H), 7.58 (m, 8H), 7.94 (d, 2H), 8.52 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 1.68 (s, 6H), 7.11 (m, 9H), 7.36 (d, s, 1 H)

[[ 준비예Preparation Example 21] Core21] Core 21 의21 합성 synthesis

Figure pat00084
Figure pat00084

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 3과 동일한 과정을 수행하여 Core 21 (57.7 g, 수율 72 %)을 얻었다.The procedure of Preparation Example 3 was repeated except that 11-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield: 72%).

1H-NMR: δ 7.16 (m, 12H), 7.67 (m, 5H), 7.92 (d, 2H), 8.52 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.16 (m, 12H), 7.67 (m, 5H), 7.92

[[ 준비예Preparation Example 22] Core22] Core 22 의22 of 합성 synthesis

Figure pat00085
Figure pat00085

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (51.2 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 4와 동일한 과정을 수행하여 Core 22 (52.9 g, 수율 66 %)을 얻었다.The same procedure as in Preparation Example 4 was carried out except that 11-bromo-7H-benzo [c] carbazole (51.2 g, 168.8 mmol) was used in place of 10-bromo-7H- g, yield 66%).

1H-NMR: δ 7.11 (m, 12H), 7.67 (m, 6H), 7.97 (d, 2H), 8.59 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.11 (m, 12H), 7.67 (m, 6H), 7.97

[[ 준비예Preparation Example 23] Core23] Core 23 의23 of 합성 synthesis

Figure pat00086
Figure pat00086

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 5와 동일한 과정을 수행하여 Core 23 (57.9 g, 수율 70 %)을 얻었다.The procedure of Preparation Example 5 was repeated except that 11-bromo-7H-benzo [c] carbazole (53.9 g, 168.8 mmol) was used instead of 10-bromo-7H- g, yield 70%).

1H-NMR: δ 7.21 (m, 12H), 7.57 (m, 6H), 7.92 (d, 2H), 8.59 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.21 (m, 12H), 7.57 (m, 6H), 7.92

[[ 준비예Preparation Example 24] Core24] Core 24 의24 합성 synthesis

Figure pat00087
Figure pat00087

10-bromo-7H-benzo[c]carbazole 대신 11-bromo-7H-benzo[c]carbazole (53.9 g, 168.8 mmol)을 사용하는 것을 제외하고는 준비예 6과 동일한 과정을 수행하여 Core 24 (53.1 g, 수율 64 %)을 얻었다.(53.1 g, 168.8 mmol) was used in place of 11-bromo-7H-benzo [c] g, yield 64%).

1H-NMR: δ 7.11 (m, 11H), 7.37 (d, 1H), 7.62 (m, 6H), 7.92 (d, 2H), 8.31 (d, 1H), 11.63 (s, 1H) 1 H-NMR:? 7.11 (m, 11H), 7.37 (d, IH), 7.62 (m, 6H), 7.92 (d, 2H), 8.31

[[ 합성예Synthetic example 1] 화합물  1] Compound 1 의1 of 합성 synthesis

Figure pat00088
Figure pat00088

질소 기류 하에서 Core 1 (5.00 g, 10.0 mmol), 2-chloro-4,6-diphenyl-1,3,5-triazine (2.67 g, 10.0 mmol), Pd2(dba)3 (0.27 g, 0.3 mmol), (t-Bu)3P (0.4 g, 2.0 mmol), sodium tert-butoxide (NaOBu-t) (1.92 g, 20.0 mmol)을 toluene (PhMe) 100 ml에 넣고 110℃에서 12시간 동안 교반하였다. 반응 종결 후 메틸렌클로라이드로 추출하고 MgSO4를 넣고 필터하였다. 필터된 유기층의 용매를 제거한 후 컬럼크로마토그래피를 이용하여 목적 화합물 (6.21 g, 수율 85 %)을 얻었다. (5.00 g, 10.0 mmol), 2-chloro-4,6-diphenyl-1,3,5-triazine (2.67 g, 10.0 mmol) and Pd 2 (dba) 3 (0.27 g, 0.3 mmol ), (t-Bu) 3 P (0.4 g, 2.0 mmol), sodium tert-butoxide (NaOBu-t) (1.92 g, 20.0 mmol) is put into a 100 ml toluene (PhMe) was stirred at 110 ℃ for 12 hours . After completion of the reaction, the reaction mixture was extracted with methylene chloride, and the mixture was filtered with MgSO 4 . After removing the solvent of the filtered organic layer, the desired compound (6.21 g, yield 85%) was obtained by column chromatography.

Mass : [(M+H)+] : 732Mass: [(M + H) < + & gt ; ]: 732

[[ 합성예Synthetic example 2] 화합물  2] Compound 6 의6 of 합성 synthesis

Figure pat00089
Figure pat00089

2-chloro-4,6-diphenyl-1,3,5-triazine 대신 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.61 g, 수율 82%)을 얻었다.4-yl) -6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) instead of 2-chloro-4,6-diphenyl-1,3,5- (6.61 g, yield 82%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 808Mass: [(M + H) < + & gt ; ]: 808

[[ 합성예Synthetic example 3] 화합물  3] Compound 9 의9 of 합성 synthesis

Figure pat00090
Figure pat00090

2-chloro-4,6-diphenyl-1,3,5-triazine 대신 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.46 g, 수율 80%)을 얻었다.2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol) was used instead of 2-chloro-4,6-diphenyl- , The target compound (6.46 g, yield 80%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 4] 화합물  4] Compound 13 의Thirteen 합성 synthesis

Figure pat00091
Figure pat00091

2-chloro-4,6-diphenyl-1,3,5-triazine 대신 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.49 g, 수율 78%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) was used instead of 2-chloro-4,6-diphenyl-1,3,5- (5.49 g, yield 78%).

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 5] 화합물  5] Compound 17 의17 합성 synthesis

Figure pat00092
Figure pat00092

2-chloro-4,6-diphenyl-1,3,5-triazine 대신 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.48 g, 수율 83%)을 얻었다.The same procedure as in Synthesis Example 1 was carried out except that 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) was used instead of 2-chloro-4,6-diphenyl-1,3,5- To obtain the desired compound (6.48 g, yield 83%).

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 6] 화합물  6] compound 15 의Fifteen 합성 synthesis

Figure pat00093
Figure pat00093

2-chloro-4,6-diphenyl-1,3,5-triazine 대신 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.32 g, 수율 81%)을 얻었다.Except that 4 - ([1,1'-biphenyl] -4-yl) -2-chloroquinazoline (3.16 g, 10.00 mmol) was used in place of 2-chloro-4,6-diphenyl- , The target compound (6.32 g, yield 81%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 7] 화합물  7] Compound 74 의74 of 합성 synthesis

Figure pat00094
Figure pat00094

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.77 g, 수율 79%)을 얻었다.Using Core 2 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- The procedure of Synthesis Example 1 was repeated to obtain the desired compound (5.77 g, yield 79%).

Mass : [(M+H)+] : 731Mass: [(M + H) < + & gt ; ]: 731

[[ 합성예Synthetic example 8] 화합물  8] compound 77 의77 of 합성 synthesis

Figure pat00095
Figure pat00095

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.81 g, 수율 72%)을 얻었다.Core 1 and Core 2 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- The target compound (5.81 g, yield 72%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 9] 화합물  9] compound 83 의83 of 합성 synthesis

Figure pat00096
Figure pat00096

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.54 g, 수율 74%)을 얻었다.Core 1 and Core 2 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (6.54 g, yield 74%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 885Mass: [(M + H) < + & gt ; ]: 885

[[ 합성예Synthetic example 10] 화합물  10] compound 86 의86 합성 synthesis

Figure pat00097
Figure pat00097

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.35 g, 수율 71%)을 얻었다.Core 2 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used in place of Core 1 and 2-chloro-4,6-diphenyl- (5.35 g, yield 71%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 11] 화합물  11] compound 93 의93 합성 synthesis

Figure pat00098
Figure pat00098

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.09 g, 수율 78%)을 얻었다.Core 2 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (6.09 g, yield 78%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : Mass: [(M + H) < + & gt ; ]:

[[ 합성예Synthetic example 12] 화합물  12] compound 94 의94 of 합성 synthesis

Figure pat00099
Figure pat00099

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 2 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.39 g, 수율 77%)을 얻었다.Core 2 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (6.36 g, yield 77%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the starting material (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 832Mass: [(M + H) < + & gt ; ]: 832

[[ 합성예Synthetic example 13] 화합물  13] Compound 25 의25 of 합성 synthesis

Figure pat00100
Figure pat00100

Core 1 대신 Core 3 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.21 g, 수율 88%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 3 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (6.21 g, yield 88%).

Mass : [(M+H)+] : 706Mass: [(M + H) < + & gt ; ]: 706

[[ 합성예Synthetic example 14] 화합물  14] Compound 32 의32 합성 synthesis

Figure pat00101
Figure pat00101

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.63 g, 수율 85%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (6.63 g, yield 85%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 15] 화합물  15] Compound 33 의33 of 합성 synthesis

Figure pat00102
Figure pat00102

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.48 g, 수율 83%)을 얻었다.Core 3 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine were used in place of Core 1 and 2-chloro-4,6- -triazine (3.88 g, 10.00 mmol), the target compound (6.48 g, yield 83%) was obtained.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 16] 화합물  16] compound 37 의37 합성 synthesis

Figure pat00103
Figure pat00103

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.56 g, 수율 82%)을 얻었다.Excluding the use of Core 3 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.56 g, yield 82%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 679Mass: [(M + H) < + & gt ; ]: 679

[[ 합성예Synthetic example 17] 화합물  17] Compound 41 의41 of 합성 synthesis

Figure pat00104
Figure pat00104

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.71 g, 수율 89%)을 얻었다.Core 3 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (6.71 g, yield 89%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 18] 화합물  18] compound 39 의39 of 합성 synthesis

Figure pat00105
Figure pat00105

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.33 g, 수율 84%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The procedure of Synthesis Example 1 was repeated except that chloroquinazoline (3.16 g, 10.00 mmol) was used to obtain the desired compound (6.33 g, yield 84%).

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 19] 화합물  19] Compound 99 의99 합성 synthesis

Figure pat00106
Figure pat00106

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.07 g, 수율 72%)을 얻었다.Using Core 4 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.07 g, yield 72%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 20] 화합물  20] compound 101 의101's 합성 synthesis

Figure pat00107
Figure pat00107

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.01 g, 수율 77%)을 얻었다.Core 4 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (6.01 g, yield 77%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 21] 화합물  21] Compound 107 의107 합성 synthesis

Figure pat00108
Figure pat00108

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.34 g, 수율 74%)을 얻었다.Core 4 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (6.34 g, yield 74%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 859Mass: [(M + H) < + & gt ; ]: 859

[[ 합성예Synthetic example 22] 화합물  22] compound 110 의110's 합성 synthesis

Figure pat00109
Figure pat00109

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.46 g, 수율 75%)을 얻었다.Core 4 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.46 g, yield 75%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 729Mass: [(M + H) < + & gt ; ]: 729

[[ 합성예Synthetic example 23] 화합물  23] Compound 117 의117's 합성 synthesis

Figure pat00110
Figure pat00110

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.96 g, 수율 79%)을 얻었다.Core 4 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.96 g, yield 79%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 24] 화합물  24] Compound 118 의118 합성 synthesis

Figure pat00111
Figure pat00111

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 4 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.79 g, 수율 72%)을 얻었다.Core 4 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used in place of Core 1 and 2-chloro-4,6- (3.66 g, 10.00 mmol), the target compound (5.79 g, yield 72%) was obtained.

Mass : [(M+H)+] : 805Mass: [(M + H) < + & gt ; ]: 805

[[ 합성예Synthetic example 25] 화합물  25] Compound 49 의49 of 합성 synthesis

Figure pat00112
Figure pat00112

Core 1 대신 Core 5 (5.00 g, 10.00 mmol)를 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.13 g, 수율 85%)을 얻었다.The procedure of Synthesis Example 1 was repeated, except that Core 5 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (6.13 g, yield 85%).

Mass : [(M+H)+] : 722Mass: [(M + H) < + & gt ; ]: 722

[[ 합성예Synthetic example 26] 화합물  26] compound 55 의55 합성 synthesis

Figure pat00113
Figure pat00113

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 5 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloro-6-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.62 g, 수율 83%)을 얻었다.Core 5 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (6.62 g, yield 83%) was obtained in the same manner as in Synthesis Example 1, except that chloro-6-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 797Mass: [(M + H) < + & gt ; ]: 797

[[ 합성예Synthetic example 27] 화합물  27] Compound 57 의57 of 합성 synthesis

Figure pat00114
Figure pat00114

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 5 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.70 g, 수율 84%)을 얻었다.Core 5 (5.00 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5-triazine and 2- (3-bromophenyl) -triazine (3.88 g, 10.00 mmol), the target compound (6.70 g, yield 84%) was obtained.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 28] 화합물  28] Compound 61 의61 of 합성 synthesis

Figure pat00115
Figure pat00115

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 5 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.69 g, 수율 82%)을 얻었다.Except that Core 5 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.69 g, yield 82%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 695Mass: [(M + H) < + & gt ; ]: 695

[[ 합성예Synthetic example 29] 화합물  29] Compound 65 의65 합성 synthesis

Figure pat00116
Figure pat00116

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 5 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.62 g, 수율 86%)을 얻었다.Core 5 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- , The target compound (6.62 g, yield 86%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 30] 화합물  30] Compound 63 의63 합성 synthesis

Figure pat00117
Figure pat00117

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 5 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.70 g, 수율 87%)을 얻었다.Core 5 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (6.70 g, yield 87%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 31] 화합물  31] Compound 123 의123 합성 synthesis

Figure pat00118
Figure pat00118

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.19 g, 수율 72%)을 얻었다.Using Core 6 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.19 g, yield 72%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 721Mass: [(M + H) < + & gt ; ]: 721

[[ 합성예Synthetic example 32] 화합물  32] compound 125 의125 합성 synthesis

Figure pat00119
Figure pat00119

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.98 g, 수율 75%)을 얻었다.Core 1 and Core 6 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (5.98 g, yield 75%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 33] 화합물  33] Compound 131 의131 합성 synthesis

Figure pat00120
Figure pat00120

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.37 g, 수율 73%)을 얻었다.Core 1 and Core 6 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (6.37 g, yield 73%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 875Mass: [(M + H) < + & gt ; ]: 875

[[ 합성예Synthetic example 34] 화합물  34] Compound 134 의134 of 합성 synthesis

Figure pat00121
Figure pat00121

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.51 g, 수율 74%)을 얻었다.Core 6 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.51 g, yield 74%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 745Mass: [(M + H) < + & gt ; ]: 745

[[ 합성예Synthetic example 35] 화합물  35] Compound 141 의141 of 합성 synthesis

Figure pat00122
Figure pat00122

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.08 g, 수율 79%)을 얻었다.Core 6 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (6.08 g, yield 79%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 36] 화합물  36] Compound 142 의142 합성 synthesis

Figure pat00123
Figure pat00123

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 6 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.32 g, 수율 77%)을 얻었다.Core 6 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (6.36 g, yield 77%) was obtained by following the same procedure as in Synthesis Example 1, except that the compound (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 822Mass: [(M + H) < + & gt ; ]: 822

[[ 합성예Synthetic example 37] 화합물  37] Compound 145 의145's 합성 synthesis

Figure pat00124
Figure pat00124

Core 1 대신 Core 7 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.63 g, 수율 77%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 7 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (5.63 g, yield 77%).

Mass : [(M+H)+] : 732Mass: [(M + H) < + & gt ; ]: 732

[[ 합성예Synthetic example 38] 화합물  38] Compound 150 의150 합성 synthesis

Figure pat00125
Figure pat00125

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 7 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.97 g, 수율 74%)을 얻었다.Core 7 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- The target compound (5.97 g, yield 74%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 808Mass: [(M + H) < + & gt ; ]: 808

[[ 합성예Synthetic example 39] 화합물  39] Compound 153 의153's 합성 synthesis

Figure pat00126
Figure pat00126

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 7 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.81 g, 수율 72%)을 얻었다.Except that Core 7 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine were used instead of Core 1 and 2-chloro-4,6- -triazine (3.88 g, 10.00 mmol), the target compound (5.81 g, yield 72%) was obtained.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 40] 화합물  40] Compound 157 의157 of 합성 synthesis

Figure pat00127
Figure pat00127

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 7 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.49 g, 수율 78%)을 얻었다.Except that Core 7 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.49 g, yield 78%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 41] 화합물  41] Compound 161 의161 합성 synthesis

Figure pat00128
Figure pat00128

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 7 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.62 g, 수율 72%)을 얻었다.Core 3 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.62 g, yield 72%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 42] 화합물  42] Compound 159 의Of 159 합성 synthesis

Figure pat00129
Figure pat00129

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 7 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.77 g, 수율 74%)을 얻었다.Core 1 and Core 7 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.77 g, yield 74%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 43] 화합물  43] Compound 219 의219 합성 synthesis

Figure pat00130
Figure pat00130

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.11 g, 수율 70%)을 얻었다.Using Core 8 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.11 g, yield 70%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 731Mass: [(M + H) < + & gt ; ]: 731

[[ 합성예Synthetic example 44] 화합물  44] Compound 221 의221 합성 synthesis

Figure pat00131
Figure pat00131

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.73 g, 수율 71%)을 얻었다.Core 5 and 2 - ([1,1'-biphenyl] -4-yl) -4- (2-chloro-4,6-diphenyl- The target compound (5.73 g, yield 71%) was obtained in the same manner as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 45] 화합물  45] Compound 227 의227 합성 synthesis

Figure pat00132
Figure pat00132

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (6.09 g, 수율 69%)을 얻었다.Core 5 and 2 - ([1,1'-biphenyl] -4-yl) -4- (2-chloro-4,6-diphenyl- (6.09 g, yield 69%) was obtained in the same manner as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 885Mass: [(M + H) < + & gt ; ]: 885

[[ 합성예Synthetic example 46] 화합물  46] Compound 230 의230 합성 synthesis

Figure pat00133
Figure pat00133

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.13 g, 수율 68%)을 얻었다.Core 8 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.13 g, yield 68%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 47] 화합물  47] Compound 237 의237 합성 synthesis

Figure pat00134
Figure pat00134

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.62 g, 수율 72%)을 얻었다.Core 8 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.62 g, yield 72%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 48] 화합물  48] Compound 238 의238 합성 synthesis

Figure pat00135
Figure pat00135

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 8 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.73 g, 수율 69%)을 얻었다.Core 8 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6- (5.66 g, yield 69%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the starting material (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 832Mass: [(M + H) < + & gt ; ]: 832

[[ 합성예Synthetic example 49] 화합물  49] Compound 169 의169 합성 synthesis

Figure pat00136
Figure pat00136

Core 1 대신 Core 9 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.43 g, 수율 77%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 9 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (5.43 g, yield 77%).

Mass : [(M+H)+] : 706Mass: [(M + H) < + & gt ; ]: 706

[[ 합성예Synthetic example 50] 화합물  50] Compound 176 의176 합성 synthesis

Figure pat00137
Figure pat00137

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 9 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.70 g, 수율 73%)을 얻었다.Core 1 (2.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- The target compound (5.70 g, yield 73%) was obtained by following the same procedure as in Synthesis Example 1 except that chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 51] 화합물  51] Compound 177 의177 합성 synthesis

Figure pat00138
Figure pat00138

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 9 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.62 g, 수율 72%)을 얻었다.Core 9 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine were used in place of Core 1 and 2-chloro-4,6- -triazine (3.88 g, 10.00 mmol), the target compound (5.62 g, yield 72%) was obtained.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 52] 화합물  52] Compound 181 의181 합성 synthesis

Figure pat00139
Figure pat00139

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 9 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.36 g, 수율 79%)을 얻었다.Except that Core 9 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.36 g, yield 79%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 679Mass: [(M + H) < + & gt ; ]: 679

[[ 합성예Synthetic example 53] 화합물  53] Compound 185 의185 합성 synthesis

Figure pat00140
Figure pat00140

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 9 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.28 g, 수율 70%)을 얻었다.Core 9 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used in place of Core 1 and 2-chloro-4,6-diphenyl- (5.28 g, yield 70%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 54] 화합물  54] Compound 183 의183 합성 synthesis

Figure pat00141
Figure pat00141

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 9 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.51 g, 수율 73%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.51 g, yield 73%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 55] 화합물  55] Compound 242 의242 합성 synthesis

Figure pat00142
Figure pat00142

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.07 g, 수율 72%)을 얻었다.Using Core 10 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (5.07 g, yield 72%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 56] 화합물  56] compound 245 의245 합성 synthesis

Figure pat00143
Figure pat00143

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.23 g, 수율 67%)을 얻었다.Core 1 and Core 10 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- The target compound (5.23 g, yield 67%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 57] 화합물  57] Compound 251 의251 합성 synthesis

Figure pat00144
Figure pat00144

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.66 g, 수율 66%)을 얻었다.Core 1 and Core 10 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (5.66 g, yield 66%) was obtained in the same manner as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 859Mass: [(M + H) < + & gt ; ]: 859

[[ 합성예Synthetic example 58] 화합물  58] Compound 254 의254 합성 synthesis

Figure pat00145
Figure pat00145

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.02 g, 수율 69%)을 얻었다.Core 10 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used in place of Core 1 and 2-chloro-4,6-diphenyl- (5.02 g, yield 69%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 729Mass: [(M + H) < + & gt ; ]: 729

[[ 합성예Synthetic example 59] 화합물  59] Compound 261 의261 합성 synthesis

Figure pat00146
Figure pat00146

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.68 g, 수율 62%)을 얻었다.Core 10 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.68 g, yield 62%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 60] 화합물  60] Compound 262 의262 합성 synthesis

Figure pat00147
Figure pat00147

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 10 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.07 g, 수율 63%)을 얻었다.Core 10 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6- (3.66 g, 10.00 mmol), the target compound (5.07 g, yield 63%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 805Mass: [(M + H) < + & gt ; ]: 805

[[ 합성예Synthetic example 61] 화합물  61] Compound 193 의193's 합성 synthesis

Figure pat00148
Figure pat00148

Core 1 대신 Core 11 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.34 g, 수율 74%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 11 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (5.34 g, yield 74%).

Mass : [(M+H)+] : 722Mass: [(M + H) < + & gt ; ]: 722

[[ 합성예Synthetic example 62] 화합물  62] Compound 199 의199 합성 synthesis

Figure pat00149
Figure pat00149

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 11 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloro-6-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.89 g, 수율 74%)을 얻었다.Core 1 and Core 11 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.89 g, yield 74%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 797Mass: [(M + H) < + & gt ; ]: 797

[[ 합성예Synthetic example 63] 화합물  63] compound 201 의Of 201 합성 synthesis

Figure pat00150
Figure pat00150

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 11 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.74 g, 수율 72%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5 -triazine (3.88 g, 10.00 mmol) was used in place of the compound obtained in Preparation Example 1 to obtain the desired compound (5.74 g, yield 72%).

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 64] 화합물  64] Compound 205 의205's 합성 synthesis

Figure pat00151
Figure pat00151

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 11 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.86 g, 수율 70%)을 얻었다.Excluding the use of Core 11 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.86 g, yield 70%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 695Mass: [(M + H) < + & gt ; ]: 695

[[ 합성예Synthetic example 65] 화합물  65] compound 209 의209's 합성 synthesis

Figure pat00152
Figure pat00152

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 11 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.47 g, 수율 71%)을 얻었다.Core 11 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- The procedure of Synthesis Example 1 was repeated to obtain the desired compound (5.47 g, yield 71%).

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 66] 화합물  66] Compound 207 의Of 207 합성 synthesis

Figure pat00153
Figure pat00153

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 11 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.62 g, 수율 73%)을 얻었다.Core 1 and Core 11 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.62 g, yield 73%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 67] 화합물  67] Compound 267 의267 합성 synthesis

Figure pat00154
Figure pat00154

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.97 g, 수율 69%)을 얻었다.Using Core 12 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- The target compound (4.97 g, yield 69%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 721Mass: [(M + H) < + & gt ; ]: 721

[[ 합성예Synthetic example 68] 화합물  68] Compound 269 의269 of 합성 synthesis

Figure pat00155
Figure pat00155

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.26 g, 수율 66%)을 얻었다.Core 1 and Core 2 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (5.26 g, yield 66%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 69] 화합물  69] Compound 275 의275 합성 synthesis

Figure pat00156
Figure pat00156

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.59 g, 수율 64%)을 얻었다.Core 1 and Core 2 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (5.59 g, yield 64%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 875Mass: [(M + H) < + & gt ; ]: 875

[[ 합성예Synthetic example 70] 화합물  70] Compound 278 의278 합성 synthesis

Figure pat00157
Figure pat00157

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.06 g, 수율 68%)을 얻었다.Core 12 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.06 g, yield 68%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 745Mass: [(M + H) < + & gt ; ]: 745

[[ 합성예Synthetic example 71] 화합물  71] Compound 285 의285 합성 synthesis

Figure pat00158
Figure pat00158

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.85 g, 수율 63%)을 얻었다.Except that Core 12 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.85 g, yield 63%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 72] 화합물  72] Compound 286 의286 합성 synthesis

Figure pat00159
Figure pat00159

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 12 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.41 g, 수율 66%)을 얻었다.Core 2 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used in place of Core 1 and 2-chloro-4,6-diphenyl- (5.41 g, yield 66%) was obtained by following the same procedure as in Synthesis Example 1, except that the compound (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 822Mass: [(M + H) < + & gt ; ]: 822

[[ 합성예Synthetic example 73] 화합물  73] Compound 433 의433 합성 synthesis

Figure pat00160
Figure pat00160

Core 1 대신 Core 13 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.24 g, 수율 58%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 13 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (4.24 g, yield 58%).

Mass : [(M+H)+] : 732Mass: [(M + H) < + & gt ; ]: 732

[[ 합성예Synthetic example 74] 화합물  74] Compound 438 의438 합성 synthesis

Figure pat00161
Figure pat00161

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 13 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.76 g, 수율 59%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- The target compound (4.76 g, yield 59%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 808Mass: [(M + H) < + & gt ; ]: 808

[[ 합성예Synthetic example 75] 화합물  75] Compound 441 의441 합성 synthesis

Figure pat00162
Figure pat00162

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 13 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.68 g, 수율 58%)을 얻었다.Core 13 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5 -triazine (3.88 g, 10.00 mmol), the target compound (4.68 g, yield: 58%) was obtained.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 76] 화합물  76] Compound 445 의445 합성 synthesis

Figure pat00163
Figure pat00163

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 13 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.73 g, 수율 53%)을 얻었다.Except that Core 13 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (3.73 g, yield 53%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 77] 화합물  77] Compound 449 의449 합성 synthesis

Figure pat00164
Figure pat00164

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 13 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.29 g, 수율 55%)을 얻었다.Core 13 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used in place of Core 1 and 2-chloro-4,6-diphenyl- (4.29 g, yield 55%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 78] 화합물  78] Compound 447 의447 합성 synthesis

Figure pat00165
Figure pat00165

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 13 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.45 g, 수율 57%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (4.45 g, yield 57%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 79] 화합물  79] compound 506 의506 합성 synthesis

Figure pat00166
Figure pat00166

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 14 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.72 g, 수율 51%)을 얻었다.Using Core 14 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- The procedure of Synthesis Example 1 was repeated to obtain the desired compound (3.72 g, yield 51%).

Mass : [(M+H)+] : 731Mass: [(M + H) < + & gt ; ]: 731

[[ 합성예Synthetic example 80] 화합물  80] Compound 509 의509's 합성 synthesis

Figure pat00167
Figure pat00167

Core 14 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.28 g, 수율 53%)을 얻었다.4-yl) -4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was added to a solution of Core 14 (5.00 g, 10.00 mmol) (4.28 g, yield 53%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 81] 화합물  81] Compound 515 의515 합성 synthesis

Figure pat00168
Figure pat00168

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 14 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.77 g, 수율 54%)을 얻었다.Core 1 (2.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.77 g, yield 54%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 885Mass: [(M + H) < + & gt ; ]: 885

[[ 합성예Synthetic example 82] 화합물  82] Compound 518 의518 합성 synthesis

Figure pat00169
Figure pat00169

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 14 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.15 g, 수율 55%)을 얻었다.Core 14 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6- diphenyl- (4.15 g, yield 55%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 83] 화합물  83] Compound 525 의525 합성 synthesis

Figure pat00170
Figure pat00170

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 14 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.06 g, 수율 52%)을 얻었다.Except that Core 14 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.06 g, yield 52%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 84] 화합물  84] Compound 526 의526 합성 synthesis

Figure pat00171
Figure pat00171

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 14 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.15 g, 수율 50%)을 얻었다.Core 14 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.66 g, 10.00 mmol), the target compound (4.15 g, yield 50%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 832Mass: [(M + H) < + & gt ; ]: 832

[[ 합성예Synthetic example 85] 화합물  85] Compound 457 의457 합성 synthesis

Figure pat00172
Figure pat00172

Core 1 대신 Core 15 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.16 g, 수율 59%)을 얻었다.The procedure of Synthesis Example 1 was repeated, except that Core 15 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (4.16 g, yield 59%).

Mass : [(M+H)+] : 706Mass: [(M + H) < + & gt ; ]: 706

[[ 합성예Synthetic example 86] 화합물  86] Compound 464 의464 합성 synthesis

Figure pat00173
Figure pat00173

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 15 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.06 g, 수율 52%)을 얻었다.Core 1 and Core 15 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.06 g, yield 52%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 87] 화합물  87] compound 465 의465 합성 synthesis

Figure pat00174
Figure pat00174

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 15 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.53 g, 수율 58%)을 얻었다.Except that Core 15 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5 -triazine (3.88 g, 10.00 mmol) was used in place of the compound obtained in Preparation Example 1 (4.53 g, yield 58%).

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 88] 화합물  88] compound 469 의469 합성 synthesis

Figure pat00175
Figure pat00175

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 15 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.87 g, 수율 57%)을 얻었다.Except that Core 15 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (3.87 g, yield 57%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 679Mass: [(M + H) < + & gt ; ]: 679

[[ 합성예Synthetic example 89] 화합물  89] Compound 473 의473 of 합성 synthesis

Figure pat00176
Figure pat00176

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 15 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.00 g, 수율 53%)을 얻었다.Core 15 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.00 g, yield 53%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 90] 화합물  90] Compound 471 의471 합성 synthesis

Figure pat00177
Figure pat00177

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 15 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.15 g, 수율 55%)을 얻었다.Core 1 and Core 15 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (4.15 g, yield 55%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 91] 화합물  91] Compound 531 의531 합성 synthesis

Figure pat00178
Figure pat00178

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.52 g, 수율 50%)을 얻었다.Using Core 16 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- The procedure of Synthesis Example 1 was repeated to obtain the desired compound (3.52 g, yield 50%).

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 92] 화합물  92] Compound 533 의533 합성 synthesis

Figure pat00179
Figure pat00179

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.83 g, 수율 49%)을 얻었다.Core 1 and Core 16 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (3.83 g, yield 49%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 93] 화합물  93] Compound 539 의539 합성 synthesis

Figure pat00180
Figure pat00180

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.54 g, 수율 53%)을 얻었다.Core 1 and Core 16 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.54 g, yield 53%) was obtained in the same manner as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 859Mass: [(M + H) < + & gt ; ]: 859

[[ 합성예Synthetic example 94] 화합물  94] Compound 542 의542 합성 synthesis

Figure pat00181
Figure pat00181

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.86 g, 수율 53%)을 얻었다.Core 16 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.86 g, yield 53%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 729Mass: [(M + H) < + & gt ; ]: 729

[[ 합성예Synthetic example 95] 화합물  95] compound 549 의549 합성 synthesis

Figure pat00182
Figure pat00182

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.62 g, 수율 48%)을 얻었다.Core 16 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.62 g, yield 48%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 96] 화합물  96] Compound 550 의550's 합성 synthesis

Figure pat00183
Figure pat00183

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 16 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.10 g, 수율 51%)을 얻었다.Core 16 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.10 g, yield 51%) was obtained by following the same procedure as in Synthesis Example 1, except that the compound (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 805Mass: [(M + H) < + & gt ; ]: 805

[[ 합성예Synthetic example 97] 화합물  97] Compound 481 의481 합성 synthesis

Figure pat00184
Figure pat00184

Core 1 대신 Core 17 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.25 g, 수율 59%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 17 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (4.25 g, yield 59%).

Mass : [(M+H)+] : 722Mass: [(M + H) < + & gt ; ]: 722

[[ 합성예Synthetic example 98] 화합물  98] Compound 486 의486 합성 synthesis

Figure pat00185
Figure pat00185

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 17 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.62 g, 수율 58%)을 얻었다.Core 1 and Core 17 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- (4.62 g, yield 58%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 797Mass: [(M + H) < + & gt ; ]: 797

[[ 합성예Synthetic example 99] 화합물  99] compound 489 의Of 489 합성 synthesis

Figure pat00186
Figure pat00186

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 17 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.38 g, 수율 55%)을 얻었다.Except that Core 17 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine were used in place of Core 1 and 2-chloro-4,6- -triazine (3.88 g, 10.00 mmol), the target compound (4.38 g, yield 55%) was obtained.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 100] 화합물  100] compound 493 의Of 493 합성 synthesis

Figure pat00187
Figure pat00187

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 17 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.61 g, 수율 52%)을 얻었다.Except that Core 17 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.61 g, yield 52%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 695Mass: [(M + H) < + & gt ; ]: 695

[[ 합성예Synthetic example 101] 화합물  101] Compound 497 의497 합성 synthesis

Figure pat00188
Figure pat00188

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 17 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.08 g, 수율 53%)을 얻었다.Core 17 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.08 g, yield 53%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 102] 화합물  102] Compound 495 의495 합성 synthesis

Figure pat00189
Figure pat00189

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 17 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.39 g, 수율 57%)을 얻었다.Core 1 and 2-chloro-4,6-diphenyl-1,3,5-triazine were used instead of Core 17 (5.00 g, 10.00 mmol) and 4- (1,1'-biphenyl- The target compound (4.39 g, yield 57%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 103] 화합물  103] Compound 554 의554 합성 synthesis

Figure pat00190
Figure pat00190

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.53 g, 수율 49%)을 얻었다.Using Core 18 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (3.53 g, yield 49%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 721Mass: [(M + H) < + & gt ; ]: 721

[[ 합성예Synthetic example 104] 화합물  104] Compound 557 의557 합성 synthesis

Figure pat00191
Figure pat00191

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.75 g, 수율 47%)을 얻었다.Core 1 and Core 18 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- The target compound (3.75 g, yield 47%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 105] 화합물  105] Compound 563 의563 합성 synthesis

Figure pat00192
Figure pat00192

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.84 g, 수율 44%)을 얻었다.Core 1 and Core 18 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (3.84 g, yield 44%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 875Mass: [(M + H) < + & gt ; ]: 875

[[ 합성예Synthetic example 106] 화합물  106] Compound 566 의566 합성 synthesis

Figure pat00193
Figure pat00193

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.72 g, 수율 50%)을 얻었다.Core 18 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.72 g, yield 50%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 745Mass: [(M + H) < + & gt ; ]: 745

[[ 합성예Synthetic example 107] 화합물  107] Compound 573 의573 합성 synthesis

Figure pat00194
Figure pat00194

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.23 g, 수율 42%)을 얻었다.Core 18 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.23 g, yield 42%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 108] 화합물  108] Compound 574 의574 합성 synthesis

Figure pat00195
Figure pat00195

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 18 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.94 g, 수율 48%)을 얻었다.Core 18 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.66 g, yield: 48%) was obtained in the same manner as in Synthesis Example 1, except that the compound (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 822Mass: [(M + H) < + & gt ; ]: 822

[[ 합성예Synthetic example 109] 화합물  109] Compound 289 의289 of 합성 synthesis

Figure pat00196
Figure pat00196

Core 1 대신 Core 19 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.05 g, 수율 69%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 19 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (5.05 g, yield 69%).

Mass : [(M+H)+] : 732Mass: [(M + H) < + & gt ; ]: 732

[[ 합성예Synthetic example 110] 화합물  110] compound 294 의294 합성 synthesis

Figure pat00197
Figure pat00197

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 19 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.32 g, 수율 66%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- The target compound (5.32 g, yield 66%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 808Mass: [(M + H) < + & gt ; ]: 808

[[ 합성예Synthetic example 111] 화합물  111] compound 297 의297 합성 synthesis

Figure pat00198
Figure pat00198

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 19 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.89 g, 수율 73%)을 얻었다.Core 19 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine were used in place of Core 1 and 2-chloro-4,6- -triazine (3.88 g, 10.00 mmol), the target compound (5.89 g, yield 73%) was obtained.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 112] 화합물  112] Compound 301 의301's 합성 synthesis

Figure pat00199
Figure pat00199

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 19 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.86 g, 수율 69%)을 얻었다.Except that Core 19 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.86 g, yield 69%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 113] 화합물  113] Compound 305 의305 합성 synthesis

Figure pat00200
Figure pat00200

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 19 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.46 g, 수율 70%)을 얻었다.Core 19 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.46 g, yield 70%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 114] 화합물  114] Compound 303 의303 합성 synthesis

Figure pat00201
Figure pat00201

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 19 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.31 g, 수율 68%)을 얻었다.Core 1 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.31 g, yield 68%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 115] 화합물  115] Compound 362 의362 합성 synthesis

Figure pat00202
Figure pat00202

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.45 g, 수율 61%)을 얻었다.Core 20 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- , The target compound (4.45 g, yield: 61%) was obtained.

Mass : [(M+H)+] : 731Mass: [(M + H) < + & gt ; ]: 731

[[ 합성예Synthetic example 116] 화합물  116] Compound 365 의365 합성 synthesis

Figure pat00203
Figure pat00203

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.84 g, 수율 60%)을 얻었다.Except that Core 20 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- The target compound (4.84 g, yield 60%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 809Mass: [(M + H) < + & gt ; ]: 809

[[ 합성예Synthetic example 117] 화합물  117] compound 371 의371 합성 synthesis

Figure pat00204
Figure pat00204

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.12 g, 수율 58%)을 얻었다. Except that Core 20 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (5.12 g, yield 58%) was obtained in the same manner as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 885Mass: [(M + H) < + & gt ; ]: 885

[[ 합성예Synthetic example 118] 화합물  118] Compound 374 의374 합성 synthesis

Figure pat00205
Figure pat00205

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.68 g, 수율 62%)을 얻었다.Core 20 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.68 g, yield 62%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 119] 화합물  119] Compound 381 의381 합성 synthesis

Figure pat00206
Figure pat00206

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.15 g, 수율 66%)을 얻었다.Core 20 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (5.15 g, yield 66%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 120] 화합물  120] Compound 382 의382 합성 synthesis

Figure pat00207
Figure pat00207

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 20 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.23 g, 수율 63%)을 얻었다.Core 20 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6- (3.63 g, 10.00 mmol) was used in place of the compound obtained in Preparation Example 1 to obtain the desired compound (5.23 g, yield 63%).

Mass : [(M+H)+] : 832Mass: [(M + H) < + & gt ; ]: 832

[[ 합성예Synthetic example 121] 화합물  121] Compound 313 의Of 313 합성 synthesis

Figure pat00208
Figure pat00208

Core 1 대신 Core 21 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.79 g, 수율 68%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that Core 21 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (4.79 g, yield 68%).

Mass : [(M+H)+] : 706Mass: [(M + H) < + & gt ; ]: 706

[[ 합성예Synthetic example 122] 화합물  122] Compound 318 의318 합성 synthesis

Figure pat00209
Figure pat00209

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 21 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.31 g, 수율 68%)을 얻었다.Core 1 and Core 21 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- The target compound (5.31 g, yield 68%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 781Mass: [(M + H) < + & gt ; ]: 781

[[ 합성예Synthetic example 123] 화합물  123] compound 321 의321 합성 synthesis

Figure pat00210
Figure pat00210

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 21 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.84 g, 수율 62%)을 얻었다.Except that Core 21 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5 -triazine (3.88 g, 10.00 mmol), the target compound (4.84 g, yield 62%) was obtained.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 124] 화합물  124] Compound 325 의325 합성 synthesis

Figure pat00211
Figure pat00211

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 21 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.48 g, 수율 66%)을 얻었다.Except that Core 21 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.48 g, yield 66%) was obtained in the same manner as in Synthesis Example 1.

Mass : [(M+H)+] : 679Mass: [(M + H) < + & gt ; ]: 679

[[ 합성예Synthetic example 125] 화합물  125] compound 329 의329 합성 synthesis

Figure pat00212
Figure pat00212

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 21 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.52 g, 수율 60%)을 얻었다.Except that Core 21 (2.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.52 g, yield 60%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 126] 화합물  126] compound 327 의327 합성 synthesis

Figure pat00213
Figure pat00213

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 21 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.20 g, 수율 69%)을 얻었다.Core 1 and Core 21 (5.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The target compound (5.20 g, yield 69%) was obtained by following the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 127] 화합물  127] compound 386 의386 합성 synthesis

Figure pat00214
Figure pat00214

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.30 g, 수율 61%)을 얻었다.Using Core 22 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.30 g, yield 61%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 합성예Synthetic example 128] 화합물  128] Compound 389 의389 합성 synthesis

Figure pat00215
Figure pat00215

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.53 g, 수율 58%)을 얻었다.Except that Core 22 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.53 g, yield 58%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 782Mass: [(M + H) < + & gt ; ]: 782

[[ 합성예Synthetic example 129] 화합물  129] Compound 395 의395 합성 synthesis

Figure pat00216
Figure pat00216

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.97 g, 수율 58%)을 얻었다.Except that Core 22 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.97 g, yield 58%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 859Mass: [(M + H) < + & gt ; ]: 859

[[ 합성예Synthetic example 130] 화합물  130] compound 398 의398 합성 synthesis

Figure pat00217
Figure pat00217

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.51 g, 수율 62%)을 얻었다.Core 22 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.51 g, yield 62%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 729Mass: [(M + H) < + & gt ; ]: 729

[[ 합성예Synthetic example 131] 화합물  131] compound 405 의405 합성 synthesis

Figure pat00218
Figure pat00218

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.98 g, 수율 66%)을 얻었다.(3.00 g, 10.00 mmol) and Core 22 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline in place of Core 1 and 2-chloro-4,6-diphenyl- (4.98 g, yield 66%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 755Mass: [(M + H) < + & gt ; ]: 755

[[ 합성예Synthetic example 132] 화합물  132] compound 406 의406 합성 synthesis

Figure pat00219
Figure pat00219

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 22 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.82 g, 수율 60%)을 얻었다.Core 22 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used in place of Core 1 and 2-chloro-4,6- (4.66 g, yield 60%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the starting material (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 805Mass: [(M + H) < + & gt ; ]: 805

[[ 합성예Synthetic example 133] 화합물  133] compound 337 의337 합성 synthesis

Figure pat00220
Figure pat00220

Core 1 대신 Core 23 (5.00 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.47 g, 수율 62%)을 얻었다.The procedure of Synthesis Example 1 was repeated, except that Core 23 (5.00 g, 10.00 mmol) was used instead of Core 1 to obtain the desired compound (4.47 g, yield 62%).

Mass : [(M+H)+] : 722Mass: [(M + H) < + & gt ; ]: 722

[[ 합성예Synthetic example 134] 화합물  134] Compound 342 의342 합성 synthesis

Figure pat00221
Figure pat00221

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 23 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-6-chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.02 g, 수율 63%)을 얻었다.Core (1.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -6- The target compound (5.02 g, yield 63%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-2-phenylpyrimidine (3.42 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 797Mass: [(M + H) < + & gt ; ]: 797

[[ 합성예Synthetic example 135] 화합물  135] compound 345 의345 합성 synthesis

Figure pat00222
Figure pat00222

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 23 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine (3.88 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (5.26 g, 수율 63%)을 얻었다.Core 23 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4,6-diphenyl-1,3,5 -triazine (3.88 g, 10.00 mmol) was used in place of the compound obtained in Synthesis Example 1 to obtain the desired compound (5.26 g, yield 63%).

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 136] 화합물  136] Compound 349 의349 합성 synthesis

Figure pat00223
Figure pat00223

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 23 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.16 g, 수율 60%)을 얻었다.Except that Core 23 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylquinazoline (2.40 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.16 g, yield 60%) was obtained by the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 695Mass: [(M + H) < + & gt ; ]: 695

[[ 합성예Synthetic example 137] 화합물  137] Compound 353 의Of 353 합성 synthesis

Figure pat00224
Figure pat00224

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 23 (5.00 g, 10.00 mmol)와 2-(3-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.70 g, 수율 61%)을 얻었다.Core 23 (5.00 g, 10.00 mmol) and 2- (3-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.70 g, yield: 61%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 138] 화합물  138] Compound 351 의351 합성 synthesis

Figure pat00225
Figure pat00225

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 23 (5.00 g, 10.00 mmol)와 4-([1,1'-biphenyl]-4-yl)-2-chloroquinazoline (3.16 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.54 g, 수율 59%)을 얻었다.Core 1 (2.00 g, 10.00 mmol) and 4 - ([1,1'-biphenyl] -4-yl) -2- The title compound (4.54 g, yield 59%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that chloroquinazoline (3.16 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 139] 화합물  139] Compound 410 의410 합성 synthesis

Figure pat00226
Figure pat00226

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.18 g, 수율 58%)을 얻었다.Using Core 24 (5.00 g, 10.00 mmol) and 4-chloro-2,6-diphenylpyrimidine (2.66 g, 10.00 mmol) instead of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- The procedure of Synthesis Example 1 was repeated to obtain the desired compound (4.18 g, yield 58%).

Mass : [(M+H)+] : 721Mass: [(M + H) < + & gt ; ]: 721

[[ 합성예Synthetic example 140] 화합물  140] Compound 413 의413 합성 synthesis

Figure pat00227
Figure pat00227

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.38 g, 수율 55%)을 얻었다.Except that Core 24 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.38 g, yield 55%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-6-phenyl-1,3,5-triazine (3.43 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 798Mass: [(M + H) < + & gt ; ]: 798

[[ 합성예Synthetic example 141] 화합물  141] Compound 419 의419 합성 synthesis

Figure pat00228
Figure pat00228

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 2-([1,1'-biphenyl]-4-yl)-4-(3-bromophenyl)-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.98 g, 수율 57%)을 얻었다.Except that Core 24 (5.00 g, 10.00 mmol) and 2 - ([1,1'-biphenyl] -4-yl) -4- (4.98 g, yield: 57%) was obtained in the same manner as in Synthesis Example 1, except that 3-bromophenyl-6-phenyl-1,3,5-triazine (4.64 g, 10.00 mmol) ≪ / RTI >

Mass : [(M+H)+] : 875Mass: [(M + H) < + & gt ; ]: 875

[[ 합성예Synthetic example 142] 화합물  142] Compound 422 의422 합성 synthesis

Figure pat00229
Figure pat00229

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 2-chloro-4-phenylbenzo[h]quinazoline (2.90 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.72 g, 수율 50%)을 얻었다.Core 24 (5.00 g, 10.00 mmol) and 2-chloro-4-phenylbenzo [h] quinazoline (2.90 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.72 g, yield 50%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that

Mass : [(M+H)+] : 745Mass: [(M + H) < + & gt ; ]: 745

[[ 합성예Synthetic example 143] 화합물  143] Compound 429 의429 합성 synthesis

Figure pat00230
Figure pat00230

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 2-(4-bromophenyl)-4-phenylquinazoline (3.61 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (3.93 g, 수율 51%)을 얻었다.Core 24 (5.00 g, 10.00 mmol) and 2- (4-bromophenyl) -4-phenylquinazoline (3.61 g, 10.00 mmol) were used instead of Core 1 and 2-chloro-4,6-diphenyl- (3.93 g, yield 51%) was obtained by carrying out the same procedure as in Synthesis Example 1. [

Mass : [(M+H)+] : 771Mass: [(M + H) < + & gt ; ]: 771

[[ 합성예Synthetic example 144] 화합물  144] compound 430 의430 합성 synthesis

Figure pat00231
Figure pat00231

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 24 (5.00 g, 10.00 mmol)와 2-chloro-4-(4-(naphthalen-1-yl)phenyl)quinazoline (3.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.51 g, 수율 55%)을 얻었다.Core 24 (5.00 g, 10.00 mmol) and 2-chloro-4- (4- (naphthalen-1-yl) phenyl) quinazoline were used instead of Core 1 and 2-chloro-4,6-diphenyl- (4.51 g, yield 55%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the starting material (3.66 g, 10.00 mmol) was used.

Mass : [(M+H)+] : 822Mass: [(M + H) < + & gt ; ]: 822

[[ 합성예Synthetic example 145] 화합물  145] Compound 27 의27 합성 synthesis

Figure pat00232
Figure pat00232

Core 1과 2-chloro-4,6-diphenyl-1,3,5-triazine 대신 Core 3 (5.00 g, 10.00 mmol)와 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol)을 사용하는 것을 제외하고는 합성예 1과 동일한 과정을 수행하여 목적 화합물 (4.23 g, 수율 60%)을 얻었다.Core 3 (5.00 g, 10.00 mmol) and 2-chloro-4,6-diphenylpyrimidine (2.66 g, 10.00 mmol) were used in place of Core 1 and 2-chloro-4,6-diphenyl-1,3,5- , The target compound (4.23 g, yield 60%) was obtained by carrying out the same procedure as in Synthesis Example 1.

Mass : [(M+H)+] : 705Mass: [(M + H) < + & gt ; ]: 705

[[ 실시예Example 1 내지 72] 적색 유기  1 to 72] Red organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

상기 합성예에서 합성한 화합물 13, 15, 17, 37, 39, 41, 61, 63, 65, 86, 93, 94, 110, 117, 118, 134, 141, 142, 157, 159, 161, 181, 183, 185, 205, 207, 209, 230, 237, 238, 254, 261, 262, 278, 285, 286, 301, 303, 305, 325, 327, 329, 349, 351, 353, 374, 381, 382, 398, 405, 406, 422, 429, 430, 445, 447, 469, 471, 473, 493, 495, 497, 518, 525, 526, 542, 549, 550, 566, 573, 574를 통상적으로 알려진 방법으로 고순도 승화정제한 후 아래의 과정에 따라 적색 유기 전계 발광 소자를 제작하였다.The compounds 13, 15, 17, 37, 39, 41, 61, 63, 65, 86, 93, 94, 110, 117, 118, 134, 141, 142, 157, 159, 161, 181 , 183, 185, 205, 207, 209, 230, 237, 238, 254, 261, 262, 278, 285, 286, 301, 303, 305, 325, 327, 329, 349, 351, 353, 374, 381 , 382, 398, 405, 406, 422, 429, 430, 445, 447, 469, 471, 473, 493, 495, 497, 518, 525, 526, 542, 549, 550, 566, 573, The red organic electroluminescent device was fabricated according to the following procedure.

먼저, ITO (Indium tin oxide)가 1500Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후 UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음 UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, a glass substrate coated with ITO (Indium Tin Oxide) with a thickness of 1500 Å was washed with distilled water ultrasonic waves. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried and transferred to a UV OZONE cleaner (Power Sonic 405, Hoshin Tech), the substrate was cleaned using UV for 5 minutes, The substrate was transferred.

이렇게 준비된 ITO 투명 전극 위에 m-MTDATA (60 nm)/TCTA (80 nm)/ 90% 표 2의 각각의 화합물 + 10 % (piq)2Ir(acac) (300 nm)/BCP (10 nm)/Alq3 (30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 전계 발광 소자를 제작하였다.M-MTDATA (60 nm) / TCTA (80 nm) / 90% Each compound of Table 2 + 10% (piq) 2 Ir (acac) (300 nm) / BCP (10 nm) / Alq 3 (30 nm) / LiF (1 nm) / Al (200 nm) were stacked in this order to fabricate an organic electroluminescent device.

[[ 비교예Comparative Example 1] 적색 유기  1] Red organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

발광층 형성시 발광 호스트 물질로서 화합물 13 대신 CBP를 사용하는 것을 제외하고는 상기 실시예 1과 동일한 과정으로 적색 유기 전계 발광 소자를 제작하였다.A red organic electroluminescent device was fabricated in the same manner as in Example 1, except that CBP was used instead of Compound 13 as a luminescent host material in forming the light emitting layer.

[[ 비교예Comparative Example 2] 적색 유기  2] Red organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

발광층 형성시 발광 호스트 물질로서 화합물 13 대신 화합물 A를 사용하는 것을 제외하고는 상기 실시예 1과 동일한 과정으로 적색 유기 전계 발광 소자를 제작하였다.A red organic electroluminescent device was fabricated in the same manner as in Example 1, except that Compound A was used instead of Compound 13 as a luminescent host material in forming the light emitting layer.

상기 실시예 1 내지 72, 비교예 1 및 2 에서 사용된 m-MTDATA, TCTA, (piq)2Ir(acac), BCP, CBP 및 화합물 A의 구조는 하기와 같다.The structures of m-MTDATA, TCTA, (piq) 2 Ir (acac), BCP, CBP and Compound A used in Examples 1 to 72 and Comparative Examples 1 and 2 are as follows.

Figure pat00233
Figure pat00233

Figure pat00234
Figure pat00235
Figure pat00234
Figure pat00235

Figure pat00236
Figure pat00236

[[ 평가예Evaluation example 1] One]

실시예 1 내지 72, 비교예 1 및 2에서 제작한 각각의 적색 유기 전계 발광 소자에 대하여 전류밀도 10 mA/㎠에서의 구동전압 및 전류효율을 측정하고, 그 결과를 하기 표 2에 나타내었다.The driving voltage and the current efficiency at a current density of 10 mA / cm 2 were measured for each of the red organic electroluminescent devices manufactured in Examples 1 to 72 and Comparative Examples 1 and 2, and the results are shown in Table 2 below.

샘플Sample 호스트Host 구동 전압(V)The driving voltage (V) 전류효율(cd/A)Current efficiency (cd / A) 실시예1Example 1 화합물13Compound 13 4.74.7 11.911.9 실시예2Example 2 화합물15Compound 15 4.74.7 11.611.6 실시예3Example 3 화합물17Compound 17 4.74.7 12.412.4 실시예4Example 4 화합물37Compound 37 4.74.7 13.213.2 실시예5Example 5 화합물39Compound 39 4.84.8 12.512.5 실시예6Example 6 화합물41Compound 41 4.84.8 12.612.6 실시예7Example 7 화합물61Compound 61 4.84.8 12.312.3 실시예8Example 8 화합물63Compound 63 4.74.7 12.212.2 실시예9Example 9 화합물65Compound 65 4.74.7 12.512.5 실시예10Example 10 화합물86Compound 86 4.84.8 11.711.7 실시예11Example 11 화합물93Compound 93 4.84.8 11.611.6 실시예12Example 12 화합물94Compound 94 4.74.7 11.511.5 실시예13Example 13 화합물110Compound 110 4.74.7 12.412.4 실시예14Example 14 화합물117Compound 117 4.84.8 12.412.4 실시예15Example 15 화합물118Compound 118 4.84.8 12.312.3 실시예16Example 16 화합물134Compound 134 4.84.8 11.711.7 실시예17Example 17 화합물141Compound 141 4.84.8 12.312.3 실시예18Example 18 화합물142Compound 142 4.84.8 12.612.6 실시예19Example 19 화합물157Compound 157 4.84.8 12.612.6 실시예20Example 20 화합물159Compound 159 4.74.7 12.412.4 실시예21Example 21 화합물161Compound 161 4.74.7 11.211.2 실시예22Example 22 화합물181Compound 181 4.74.7 11.111.1 실시예23Example 23 화합물183Compound 183 4.74.7 11.311.3 실시예24Example 24 화합물185Compound 185 4.74.7 11.511.5 실시예25Example 25 화합물205Compound 205 4.84.8 12.312.3 실시예26Example 26 화합물207Compound 207 4.84.8 12.212.2 실시예27Example 27 화합물209Compound 209 4.84.8 12.212.2 실시예28Example 28 화합물230Compound 230 4.74.7 11.311.3 실시예29Example 29 화합물237Compound 237 4.74.7 11.411.4 실시예30Example 30 화합물238Compound 238 4.74.7 12.512.5 실시예31Example 31 화합물254Compound 254 4.84.8 12.412.4 실시예32Example 32 화합물261Compound 261 4.84.8 12.212.2 실시예33Example 33 화합물262Compound 262 4.74.7 11.711.7 실시예34Example 34 화합물278Compound 278 4.84.8 11.511.5 실시예35Example 35 화합물285Compound 285 4.74.7 12.412.4 실시예36Example 36 화합물286Compound 286 4.84.8 12.612.6 실시예37Example 37 화합물301Compound 301 4.74.7 12.412.4 실시예38Example 38 화합물303Compound 303 4.84.8 11.211.2 실시예39Example 39 화합물305Compound 305 4.74.7 11.511.5 실시예40Example 40 화합물325Compound 325 4.84.8 11.611.6 실시예41Example 41 화합물327Compound 327 4.84.8 12.612.6 실시예42Example 42 화합물329Compound 329 4.84.8 12.412.4 실시예43Example 43 화합물349Compound 349 4.84.8 12.412.4 실시예44Example 44 화합물351Compound 351 4.84.8 11.311.3 실시예45Example 45 화합물353Compound 353 4.74.7 12.512.5 실시예46Example 46 화합물374Compound 374 4.74.7 12.612.6 실시예47Example 47 화합물381Compound 381 4.84.8 12.712.7 실시예48Example 48 화합물382Compound 382 4.84.8 11.811.8 실시예49Example 49 화합물398Compound 398 4.84.8 12.912.9 실시예50Example 50 화합물405Compound 405 4.74.7 12.912.9 실시예51Example 51 화합물406Compound 406 4.74.7 12.712.7 실시예52Example 52 화합물422Compound 422 4.74.7 12.712.7 실시예53Example 53 화합물429Compound 429 4.84.8 11.611.6 실시예54Example 54 화합물430Compound 430 4.84.8 11.411.4 실시예55Example 55 화합물445Compound 445 4.84.8 11.311.3 실시예56Example 56 화합물447Compound 447 4.84.8 12.212.2 실시예57Example 57 화합물449Compound 449 4.84.8 12.312.3 실시예58Example 58 화합물469Compound 469 4.84.8 12.412.4 실시예59Example 59 화합물471Compound 471 4.94.9 12.512.5 실시예60Example 60 화합물473Compound 473 4.84.8 12.612.6 실시예61Example 61 화합물493Compound 493 4.74.7 11.311.3 실시예62Example 62 화합물495Compound 495 4.84.8 11.211.2 실시예63Example 63 화합물497Compound 497 4.74.7 11.511.5 실시예64Example 64 화합물518Compound 518 4.84.8 11.711.7 실시예65Example 65 화합물525Compound 525 4.84.8 11.811.8 실시예66Example 66 화합물526Compound 526 4.84.8 12.512.5 실시예67Example 67 화합물542Compound 542 4.74.7 12.412.4 실시예68Example 68 화합물549Compound 549 4.84.8 12.212.2 실시예69Example 69 화합물550Compound 550 4.74.7 12.312.3 실시예70Example 70 화합물566Compound 566 4.84.8 12.512.5 실시예71Example 71 화합물573Compound 573 4.84.8 11.711.7 실시예72Example 72 화합물574Compound 574 4.84.8 11.811.8 비교예 1Comparative Example 1 CBPCBP 5.255.25 8.28.2 비교예 2Comparative Example 2 화합물 ACompound A 5.125.12 9.79.7

상기 표 2에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층에 사용한 적색 유기 전계 발광 소자(실시예 1 내지 72)는 CBP 또는 화합물 A를 발광층에 사용한 적색 유기 전계 발광 소자(비교예 1 또는 2)에 비해 전류효율 및 구동전압 면에서 보다 우수한 성능을 나타내는 것을 알 수 있었다.As shown in Table 2, the red organic electroluminescent devices (Examples 1 to 72) using the compound according to the present invention in the light emitting layer were red organic electroluminescent devices (Comparative Example 1 or 2) using CBP or Compound A as the light emitting layer, Which is superior in current efficiency and driving voltage.

또한, 실시예 1, 5, 7, 8, 10, 13, 19, 22, 25, 28, 31 및 34, 비교예 1 및 2에서 제작한 각각의 적색 유기 전계 발광 소자에 대하여 수명(T90: 초기 휘도에서 90%로 감소하는데 소요되는 시간)을 측정하고, 그 결과를 하기 표 3에 나타내었다.Further, for each red organic electroluminescent device manufactured in Examples 1, 5, 7, 8, 10, 13, 19, 22, 25, 28, 31 and 34 and Comparative Examples 1 and 2, the lifetime The time required for the luminance to decrease to 90%) was measured. The results are shown in Table 3 below.

샘플Sample 호스트Host 수명 (T90)Life (T90) 실시예 1Example 1 화합물 13Compound 13 8080 실시예 5Example 5 화합물 39Compound 39 8585 실시예 7Example 7 화합물 61Compound 61 9090 실시예 8Example 8 화합물 63Compound 63 7575 실시예 10Example 10 화합물 86Compound 86 7070 실시예 13Example 13 화합물 110Compound 110 8585 실시예 19Example 19 화합물 157Compound 157 6565 실시예 22Example 22 화합물 181Compound 181 7070 실시예 25Example 25 화합물 205Compound 205 8585 실시예 28Example 28 화합물 230Compound 230 8080 실시예 31Example 31 화합물 254Compound 254 6565 실시예 34Example 34 화합물 278Compound 278 6060 비교예 1Comparative Example 1 CBPCBP 20 20 비교예 2Comparative Example 2 화합물 ACompound A 4040

상기 표 3에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층에 사용한 적색 유기 전계 발광 소자(실시예 1, 5, 7, 8, 10, 13, 19, 22, 25, 28, 31 및 34)는 CBP 또는 화합물 A를 발광층에 사용한 적색 유기 전계 발광 소자(비교예 1 또는 2)에 비해 긴 수명을 나타내는 것을 알 수 있었다.As shown in Table 3, the red organic electroluminescent devices (Examples 1, 5, 7, 8, 10, 13, 19, 22, 25, 28, 31 and 34) using the compound according to the present invention in the light- (Comparative Example 1 or 2) using CBP or Compound A as a light emitting layer.

[[ 실시예Example 73 내지 145] 녹색 유기  73 to 145] Green organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

상기 합성예에서 합성한 화합물 1, 6, 9, 25, 27, 32, 33, 49, 55, 57, 74, 77, 83, 99, 101, 107, 123, 125, 131, 145, 150, 153, 169, 176, 177, 193, 199, 201, 219, 221, 227, 242, 245, 251, 267, 269, 275, 289, 294, 297, 313, 318, 321, 337, 342, 345, 362, 365, 371, 386, 389, 395, 410, 413, 419, 433, 438, 441, 457, 464, 465, 481, 486, 489, 506, 509, 515, 531, 533, 539, 554, 557, 563을 통상적으로 알려진 방법으로 고순도 승화정제한 후 아래의 과정에 따라 녹색 유기 전계 발광 소자를 제작하였다.The compounds 1, 6, 9, 25, 27, 32, 33, 49, 55, 57, 74, 77, 83, 99, 101, 107, 123, 125, 131, 145, 150, 153 , 169, 176, 177, 193, 199, 201, 219, 221, 227, 242, 245, 251, 267, 269, 275, 289, 294, 297, 313, 318, 321, 337, 342, 345, 362 , 365, 371, 386, 389, 395, 410, 413, 419, 433, 438, 441, 457, 464, 465, 481, 486, 489, 506, 509, 515, 531, 533, 539, 554, 557 , 563 were purified by high purity sublimation by a conventionally known method, and then a green organic electroluminescent device was fabricated according to the following procedure.

먼저, ITO (Indium tin oxide)가 1500Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후 UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음 UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, a glass substrate coated with ITO (Indium Tin Oxide) with a thickness of 1500 Å was washed with distilled water ultrasonic waves. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried and transferred to a UV OZONE cleaner (Power Sonic 405, Hoshin Tech), the substrate was cleaned using UV for 5 minutes, The substrate was transferred.

이렇게 준비된 ITO 투명 전극 위에 m-MTDATA (60 nm)/TCTA (80 nm)/ 90% 표 4의 각각의 화합물 + 10 % Ir(ppy)3 (300 nm)/BCP (10 nm)/Alq3 (30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 전계 발광 소자를 제작하였다. M-MTDATA (60 nm) / TCTA (80 nm) / 90% Each compound of Table 4 + 10% Ir (ppy) 3 (300 nm) / BCP (10 nm) / Alq 3 30 nm) / LiF (1 nm) / Al (200 nm) were stacked in this order to fabricate an organic electroluminescent device.

[[ 비교예Comparative Example 3] 녹색 유기  3] Green organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

발광층 형성시 발광 호스트 물질로서 화합물 1 대신 CBP를 사용하는 것을 제외하고는 실시예 73 과 동일한 과정으로 녹색 유기 전계 발광 소자를 제작하였다.A green organic electroluminescent device was fabricated in the same manner as in Example 73, except that CBP was used instead of Compound 1 as a luminescent host material in forming the light emitting layer.

[[ 비교예Comparative Example 4] 녹색 유기  4] Green organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

발광층 형성시 발광 호스트 물질로서 화합물 1 대신 화합물 B 를 사용하는 것을 제외하고는 실시예 73 과 동일한 과정으로 녹색 유기 전계 발광 소자를 제작하였다.A green organic electroluminescent device was fabricated in the same manner as in Example 73, except that Compound B was used instead of Compound 1 as a luminescent host material in forming the light emitting layer.

[[ 비교예Comparative Example 5] 녹색 유기  5] Green organic 전계Field 발광 소자의 제작 Fabrication of light emitting device

발광층 형성시 발광 호스트 물질로서 화합물 1 대신 화합물 C 를 사용하는 것을 제외하고는 실시예 73 과 동일한 과정으로 녹색 유기 전계 발광 소자를 제작하였다.A green organic electroluminescent device was fabricated in the same manner as in Example 73, except that Compound C was used instead of Compound 1 as a luminescent host material in forming the light emitting layer.

상기 Ir(ppy)3, 화합물 B 및 화합물 C의 구조는 하기와 같다.The structures of Ir (ppy) 3 , Compound B and Compound C are as follows.

Figure pat00237
Figure pat00238
Figure pat00239
Figure pat00237
Figure pat00238
Figure pat00239

[[ 평가예Evaluation example 2] 2]

실시예 73 내지 145, 비교예 3 내지 5 에서 제작한 각각의 녹색 유기 전계 발광 소자에 대하여 전류밀도 10 mA/㎠에서의 구동전압, 전류효율 및 발광 피크를 측정하고, 그 결과를 하기 표 4에 나타내었다.Current efficiency and emission peak at current density of 10 mA / cm < 2 > were measured for each of the green organic electroluminescent devices manufactured in Examples 73 to 145 and Comparative Examples 3 to 5, Respectively.

샘플Sample 호스트Host 구동 전압
(V)
Driving voltage
(V)
EL 피크
(nm)
EL peak
(nm)
전류효율
(cd/A)
Current efficiency
(cd / A)
실시예 73Example 73 화합물1Compound 1 6.16.1 516516 42.942.9 실시예 74Example 74 화합물6Compound 6 6.16.1 517517 42.842.8 실시예 75Example 75 화합물9Compound 9 6.16.1 518518 42.742.7 실시예 76Example 76 화합물25Compound 25 6.16.1 518518 43.843.8 실시예 77Example 77 화합물27Compound 27 6.26.2 517517 43.543.5 실시예 78Example 78 화합물32Compound 32 6.16.1 517517 43.343.3 실시예 79Example 79 화합물33Compound 33 6.16.1 516516 43.643.6 실시예 80Example 80 화합물49Compound 49 6.26.2 517517 42.342.3 실시예 81Example 81 화합물55Compound 55 6.26.2 518518 42.542.5 실시예 82Example 82 화합물57Compound 57 6.26.2 518518 42.642.6 실시예 83Example 83 화합물74Compound 74 6.26.2 517517 43.343.3 실시예 84Example 84 화합물77Compound 77 6.16.1 518518 43.443.4 실시예 85Example 85 화합물83Compound 83 6.16.1 517517 43.743.7 실시예 86Example 86 화합물99Compound 99 6.16.1 518518 42.342.3 실시예 87Example 87 화합물101Compound 101 6.26.2 515515 42.342.3 실시예 88Example 88 화합물107Compound 107 6.26.2 516516 42.442.4 실시예 89Example 89 화합물123Compound 123 6.26.2 516516 42.742.7 실시예 90Example 90 화합물125Compound 125 6.26.2 517517 42.542.5 실시예 91Example 91 화합물131Compound 131 6.26.2 518518 43.643.6 실시예 92Example 92 화합물145Compound 145 6.16.1 518518 43.743.7 실시예 93Example 93 화합물150Compound 150 6.16.1 517517 43.643.6 실시예 94Example 94 화합물153Compound 153 6.16.1 516516 43.443.4 실시예 95Example 95 화합물169Compound 169 6.16.1 517517 43.343.3 실시예 96Example 96 화합물176Compound 176 6.16.1 518518 42.542.5 실시예 97Example 97 화합물177Compound 177 6.26.2 518518 42.642.6 실시예 98Example 98 화합물193Compound 193 6.26.2 517517 42.442.4 실시예 99Example 99 화합물199Compound 199 6.26.2 518518 43.243.2 실시예 100Example 100 화합물201Compound 201 6.26.2 517517 43.443.4 실시예 101Example 101 화합물219Compound 219 6.16.1 518518 42.642.6 실시예 102Example 102 화합물221Compound 221 6.26.2 515515 43.743.7 실시예 103Example 103 화합물227Compound 227 6.26.2 516516 42.542.5 실시예 104Example 104 화합물242Compound 242 6.16.1 516516 43.443.4 실시예 105Example 105 화합물245Compound 245 6.26.2 517517 42.342.3 실시예 106Example 106 화합물251Compound 251 6.16.1 518518 43.343.3 실시예 107Example 107 화합물267Compound 267 6.26.2 518518 42.442.4 실시예 108Example 108 화합물269Compound 269 6.26.2 517517 43.543.5 실시예 109Example 109 화합물275Compound 275 6.16.1 516516 42.642.6 실시예 110Example 110 화합물289Compound 289 6.16.1 517517 43.643.6 실시예 111Example 111 화합물294Compound 294 6.16.1 518518 43.743.7 실시예 112Example 112 화합물297Compound 297 6.16.1 518518 43.743.7 실시예 113Example 113 Synthesis of 화합물313Compound 313 6.16.1 517517 43.643.6 실시예 114Example 114 화합물318Compound 318 6.26.2 518518 42.642.6 실시예 115Example 115 화합물321Compound 321 6.26.2 517517 42.542.5 실시예 116Example 116 화합물337Compound 337 6.26.2 518518 42.542.5 실시예 117Example 117 화합물342Compound 342 6.26.2 515515 42.342.3 실시예 118Example 118 화합물345Compound 345 6.26.2 516516 42.442.4 실시예 119Example 119 화합물362Compound 362 6.16.1 516516 43.543.5 실시예 120Example 120 화합물365Compound 365 6.16.1 517517 43.643.6 실시예 121Example 121 화합물371Compound 371 6.16.1 518518 43.643.6 실시예 122Example 122 화합물386Compound 386 6.16.1 518518 43.443.4 실시예 123Example 123 화합물389Compound 389 6.26.2 517517 43.243.2 실시예 124Example 124 화합물395Compound 395 6.26.2 516516 42.242.2 실시예 125Example 125 화합물410Compound 410 6.26.2 517517 42.142.1 실시예 126Example 126 화합물413Compound 413 6.26.2 518518 42.142.1 실시예 127Example 127 화합물419Compound 419 6.16.1 518518 42.042.0 실시예 128Example 128 화합물433Compound 433 6.16.1 517517 42.042.0 실시예 129Example 129 화합물438Compound 438 6.16.1 518518 43.943.9 실시예 130Example 130 화합물441Compound 441 6.26.2 517517 43.943.9 실시예 131Example 131 화합물457Compound 457 6.26.2 518518 43.843.8 실시예 132Example 132 화합물464Compound 464 6.16.1 515515 42.642.6 실시예 133Example 133 화합물465Compound 465 6.16.1 516516 42.642.6 실시예 134Example 134 화합물481Compound 481 6.26.2 516516 43.743.7 실시예 135Example 135 화합물486Compound 486 6.26.2 517517 43.743.7 실시예 136Example 136 화합물489Compound 489 6.26.2 518518 43.243.2 실시예 137Example 137 화합물506Compound 506 6.16.1 518518 43.243.2 실시예 138Example 138 화합물509Compound 509 6.16.1 517517 42.342.3 실시예 139Example 139 화합물515Compound 515 6.16.1 516516 42.842.8 실시예 140Example 140 화합물531Compound 531 6.26.2 517517 42.942.9 실시예 141Example 141 화합물533Compound 533 6.26.2 518518 43.743.7 실시예 142Example 142 [ 화합물539Compound 539 6.26.2 518518 43.343.3 실시예 143Example 143 화합물554Compound 554 6.26.2 517517 43.543.5 실시예 144Example 144 화합물557Compound 557 6.16.1 518518 42.942.9 실시예 145Example 145 화합물563Compound 563 6.16.1 517517 42.342.3 비교예 3Comparative Example 3 CBPCBP 6.93 6.93 516516 38.2 38.2 비교예 4Comparative Example 4 화합물BCompound B 6.86.8 515515 40.240.2 비교예 5Comparative Example 5 화합물CCompound C 6.56.5 516516 39.639.6

상기 표4에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층에 사용한 녹색 유기 전계 발광 소자(실시예 73 내지 145)는 CBP, 화합물 B 또는 화합물 C를 발광층에 사용한 녹색 유기 전계 발광 소자(비교예 3, 4 또는 5)에 비해 전류효율 및 구동전압 면에서 보다 우수한 성능을 나타내는 것을 알 수 있었다.As shown in Table 4, the green organic electroluminescent devices (Examples 73 to 145) using the compound according to the present invention in the light emitting layer were the same as the green organic electroluminescent devices using the CBP, Compound B or Compound C in the light emitting layer , 4, or 5), the current efficiency and the driving voltage were superior to each other.

또한, 실시예 73, 75, 76, 79, 85, 89, 91, 93, 94, 96, 97, 99, 비교예 3 내지 5에서 제작한 각각의 녹색 유기 전계 발광 소자에 대하여 수명(T90: 초기 휘도에서 90%로 감소하는데 소요되는 시간)을 측정하고, 그 결과를 하기 표 5에 나타내었다.The green organic electroluminescent devices fabricated in Examples 73, 75, 76, 79, 85, 89, 91, 93, 94, 96, 97 and 99, The time required for the luminance to decrease to 90%) was measured. The results are shown in Table 5 below.

샘플Sample 호스트Host 수명 (T95)Lifetime (T95) 실시예 73Example 73 화합물1Compound 1 2525 실시예 75Example 75 화합물9Compound 9 3030 실시예 76Example 76 화합물25Compound 25 3535 실시예 79Example 79 화합물49Compound 49 3030 실시예 85Example 85 화합물99Compound 99 4040 실시예 89Example 89 화합물125Compound 125 2525 실시예 91Example 91 화합물145Compound 145 2020 실시예 93Example 93 화합물153Compound 153 3030 실시예 94Example 94 화합물169Compound 169 2525 실시예 96Example 96 화합물177Compound 177 4040 실시예 97Example 97 화합물193Compound 193 3030 실시예 99Example 99 화합물201Compound 201 3535 비교예 3Comparative Example 3 CBPCBP 10 10 비교예 4Comparative Example 4 화합물 BCompound B 1515 비교예 5Comparative Example 5 화합물 CCompound C 1515

상기 표 5에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층에 사용한 녹색 유기 전계 발광 소자(실시예 73, 75, 76, 79, 85, 89, 91, 93, 94, 96, 97, 99)는 CBP, 화합물 B 또는 화합물 C를 발광층에 사용한 녹색 유기 전계 발광 소자(비교예 3, 4 또는 5)에 비해 긴 수명을 나타내는 것을 알 수 있었다. The green organic electroluminescent devices (Examples 73, 75, 76, 79, 85, 89, 91, 93, 94, 96, 97, and 99) using the compound according to the present invention in the light emitting layer (Comparative Example 3, 4 or 5) in which CBP, Compound B or Compound C was used for the light emitting layer.

Claims (9)

하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure pat00240

상기 화학식 1에서,
L1 및 L2는 서로 동일하거나 상이하며, 각각 독립적으로 단일결합이거나, 혹은 C6~C18의 아릴렌기 및 핵원자수 5 내지 18개의 헤테로아릴렌기로 이루어진 군에서 선택되고,
복수의 R1은 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기 및 C2~C40의 알키닐기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, 다만 적어도 하나 이상의 축합 고리를 형성하고,
B는 하기 화학식 2로 표시되는 치환체이고,
[화학식 2]
Figure pat00241

상기 화학식 2에서,
*은 상기 화학식 1에 결합되는 부분을 의미하고,
X는 C(R3)(R4), O 및 S로 이루어진 군으로부터 선택되고,
Ar1 및 Ar2는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되고,
m은 0 내지 3의 정수이고,
R2 내지 R4는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있고,
상기 L1 및 L2의 아릴렌기 및 헤테로아릴렌기와, 상기 Ar1 및 Ar2, R1 내지 R4의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.
A compound represented by the following formula (1):
[Chemical Formula 1]
Figure pat00240

In Formula 1,
L 1 and L 2 are the same or different and are each independently a single bond or a group selected from the group consisting of a C 6 to C 18 arylene group and a heteroarylene group having 5 to 18 nucleus atoms,
Plural R 1 are the same or different and are each independently hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group and C 2 ~ C Or an alkynyl group having 1 to 40 carbon atoms, or may be bonded to adjacent groups to form a condensed ring, but at least one condensed ring is formed,
B is a substituent represented by the following formula (2)
(2)
Figure pat00241

In Formula 2,
* Represents a moiety bonded to Formula 1,
X is selected from the group consisting of C (R 3 ) (R 4 ), O and S,
Ar 1 and Ar 2 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C the group of boron 60 aryl, C 6 ~ C 60 aryl phosphine group, is selected from the group consisting of C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of,
m is an integer of 0 to 3,
R 2 to R 4 are the same or different, each independently represent hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ alkenyl group of the C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C group of 60 arylboronic, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ selected from the group consisting of an aryl amine of the C 60 of or, or adjacent groups bonded fused to the A ring can be formed,
Wherein L 1, and arylene group of L 2 and a heteroarylene group, an alkyl group of said Ar 1 and Ar 2, R 1 to R 4, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, An alkyl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, an aryl group, A nitro group, a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C An aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 ~ C 60 aryl silyl group, C 1 ~ C 40 alkyl boron group, C 6 ~ C of the group 60 arylboronic of, C 6 ~ C 60 aryl phosphine group, C 6 ~ aryl phosphine oxide of the C 60 group And C 6 -C An arylamine group having 1 to 60 carbon atoms, and when the substituent is plural, they may be the same or different from each other.
제1항에 있어서,
상기 Ar1 및 Ar2는 서로 동일하거나 상이하며, 각각 독립적으로 C1~C40의 알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되는 것인 화합물.
The method according to claim 1,
Wherein Ar 1 and Ar 2 are the same or different and each independently represents a C 1 to C 40 alkyl group, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, and a C 6 to C 60 An arylamine group, and an arylamine group.
제1항에 있어서,
상기 화학식 1로 표시되는 화합물은 하기 화학식 3 내지 5 중 적어도 어느 하나로 표시되는 것인 화합물.
[화학식 3]
Figure pat00242

[화학식 4]
Figure pat00243

[화학식 5]
Figure pat00244

상기 화학식 3 내지 5에서,
L1, L2, Ar1, Ar2, m, R2는 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein the compound represented by the formula (1) is represented by at least one of the following formulas (3) to (5).
(3)
Figure pat00242

[Chemical Formula 4]
Figure pat00243

[Chemical Formula 5]
Figure pat00244

In the above formulas 3 to 5,
L 1 , L 2 , Ar 1 , Ar 2 , m and R 2 are as defined in claim 1, respectively.
제1항에 있어서,
상기 화학식 1로 표시되는 화합물은 하기 화학식 6 내지 8 중 적어도 어느 하나로 표시되는 것인 화합물.
[화학식 6]
Figure pat00245

[화학식 7]
Figure pat00246

[화학식 8]
Figure pat00247

상기 화학식 6 내지 8에서,
L1, L2, Ar1, Ar2, m, R2는 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein the compound represented by the formula (1) is represented by at least one of the following formulas (6) to (8).
[Chemical Formula 6]
Figure pat00245

(7)
Figure pat00246

[Chemical Formula 8]
Figure pat00247

In the above formulas (6) to (8)
L 1 , L 2 , Ar 1 , Ar 2 , m and R 2 are as defined in claim 1, respectively.
제1항에 있어서,
상기 Ar1은 하기 화학식 9로 표시되는 치환체인 것인 화합물.
[화학식 9]
Figure pat00248

상기 화학식 9에서,
*는 상기 화학식 1에 결합되는 부분을 의미하고,
Z1 내지 Z5는 서로 동일하거나 상이하며, 각각 독립적으로 N 또는 C(R5)이고, 이때 상기 R5이 복수인 경우, 이들은 서로 동일하거나 상이하고,
R5는 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있고,
상기 R5의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.
The method according to claim 1,
Wherein Ar < 1 > is a substituent represented by the following formula (9).
[Chemical Formula 9]
Figure pat00248

In the above formula (9)
* Represents a moiety bonded to Formula 1,
Z 1 to Z 5 are the same or different and each independently N or C (R 5 ), wherein when R 5 is plural, they are the same or different,
R 5 is hydrogen, deuterium (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 3 ~ C 40 of the A cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, an aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 An aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, a C 6 to C 60 An arylphosphine group, an arylphosphine oxide group having 6 to 60 carbon atoms, and an arylamine group having 6 to 60 carbon atoms, or may be bonded to an adjacent group to form a condensed ring,
Alkyl groups of the R 5, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkyl boron group, an aryl boron group, an aryl phosphine group, aryl phosphine oxide group and an arylamine group each independently a heavy hydrogen (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C A C 3 to C 40 cycloalkyl group, a heterocyclic cycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkenyl group, C 6 -C 60 aryloxy groups, C 1 -C 40 alkylsilyl groups, C 6 -C 60 arylsilyl groups, C 1 -C 40 alkylboron groups, C 6 -C 60 the arylboronic group, C 6 ~ C 60 aryl phosphine group, substituted with one or more substituents selected from the group consisting of an aryl amine of the C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 of And when the substituent is plural, they may be the same or different from each other.
제5항에 있어서,
상기 화학식 9로 표시되는 치환체는 하기 A-1 내지 A-15 중 어느 하나로 표시되는 것인 화합물.
Figure pat00249

상기 A-1 내지 A-15 에서,
R5는 제5항에서 정의한 바와 같고,
p는 0 내지 4의 정수이고,
R6은 수소, 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 혹은 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, 상기 R6이 복수인 경우, 이들은 서로 동일하거나 상이할 수 있고,
상기 R6의 알킬기, 알케닐기, 알키닐기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상의 치환기로 치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 상이할 수 있다.
6. The method of claim 5,
The substituent represented by the formula (9) is represented by any one of the following A-1 to A-15.
Figure pat00249

In the above A-1 to A-15,
R < 5 > is as defined in claim 5,
p is an integer of 0 to 4,
R 6 is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, C 3 to C 40 A cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, an aryl group having 6 to 60 carbon atoms, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 An aryloxy group, a C 1 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, a C 6 to C 60 an aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ selected from the group consisting of an aryl amine of the C 60 of, or by groups coupled to or adjacent to can form a fused ring, wherein R 6 a plurality , They may be the same or different from each other,
Alkyl group of the R 6, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkyl boron group, an aryl boron group, an aryl phosphine group, aryl phosphine oxide group and an arylamine group each independently a heavy hydrogen (D), a halogen, a cyano group, a nitro group, C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C A C 3 to C 40 cycloalkyl group, a heterocyclic cycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkenyl group, C 6 -C 60 aryloxy groups, C 1 -C 40 alkylsilyl groups, C 6 -C 60 arylsilyl groups, C 1 -C 40 alkylboron groups, C 6 -C 60 the arylboronic group, C 6 ~ C 60 aryl phosphine group, substituted with one or more substituents selected from the group consisting of an aryl amine of the C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 of And when the substituent is plural, they may be the same or different from each other.
양극, 음극 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하고,
상기 1층 이상의 유기물층 중 적어도 하나는 제1항 내지 제6항 중 어느 한 항에 기재된 화합물을 포함하는 것인 유기 전계 발광 소자.
An organic electroluminescent device comprising a cathode, a cathode, and at least one organic layer interposed between the anode and the cathode,
Wherein at least one of the one or more organic layers includes the compound according to any one of claims 1 to 6.
제7항에 있어서,
상기 화합물을 포함하는 유기물층은 정공 주입층, 정공 수송층, 발광 보조층, 발광층, 전자 수송층 및 전자 주입층으로 이루어진 군에서 선택되는 것인 유기 전계 발광 소자.
8. The method of claim 7,
Wherein the organic compound layer containing the compound is selected from the group consisting of a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer, and an electron injecting layer.
제8항에 있어서,
상기 화합물을 포함하는 유기물층은 인광 발광층인 유기 전계 발광 소자.
9. The method of claim 8,
Wherein the organic compound layer containing the compound is a phosphorescent light-emitting layer.
KR1020160133400A 2016-10-14 2016-10-14 Organic compound and organic electroluminescent device using the same KR102673121B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020160133400A KR102673121B1 (en) 2016-10-14 2016-10-14 Organic compound and organic electroluminescent device using the same
PCT/KR2017/011329 WO2018070835A1 (en) 2016-10-14 2017-10-13 Organic compound and organic electroluminescent element using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160133400A KR102673121B1 (en) 2016-10-14 2016-10-14 Organic compound and organic electroluminescent device using the same

Publications (2)

Publication Number Publication Date
KR20180041361A true KR20180041361A (en) 2018-04-24
KR102673121B1 KR102673121B1 (en) 2024-06-07

Family

ID=61905772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160133400A KR102673121B1 (en) 2016-10-14 2016-10-14 Organic compound and organic electroluminescent device using the same

Country Status (2)

Country Link
KR (1) KR102673121B1 (en)
WO (1) WO2018070835A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988154A (en) * 2019-01-16 2019-07-09 浙江华显光电科技有限公司 A kind of phosphorescence host compound and its organic electroluminescence device using the compound

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390783A (en) * 2019-08-19 2021-02-23 北京鼎材科技有限公司 Compound, application thereof and organic electroluminescent device comprising compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001160489A (en) 1999-12-01 2001-06-12 Toyota Central Res & Dev Lab Inc Organic electroluminescent element
WO2014204464A1 (en) * 2013-06-20 2014-12-24 Universal Display Corporation Phosphorescent organic light emitting devices having a hole-transporting host in the emissive region
KR20150138105A (en) * 2014-05-29 2015-12-09 주식회사 엘지화학 Hetero-cyclic compound and organic light emitting device comprising the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014103212A (en) * 2012-11-19 2014-06-05 Samsung Display Co Ltd Organic el material containing amine derivative having acridine moiety and carbazole moiety, and organic el element using the same
KR101512012B1 (en) * 2013-02-14 2015-04-16 (주)씨에스엘쏠라 Organic light compound and organic light device using the same
KR102169447B1 (en) * 2013-05-31 2020-10-23 에스에프씨 주식회사 An organoelectro luminescent compounds and organoelectro luminescent device using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001160489A (en) 1999-12-01 2001-06-12 Toyota Central Res & Dev Lab Inc Organic electroluminescent element
WO2014204464A1 (en) * 2013-06-20 2014-12-24 Universal Display Corporation Phosphorescent organic light emitting devices having a hole-transporting host in the emissive region
KR20150138105A (en) * 2014-05-29 2015-12-09 주식회사 엘지화학 Hetero-cyclic compound and organic light emitting device comprising the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988154A (en) * 2019-01-16 2019-07-09 浙江华显光电科技有限公司 A kind of phosphorescence host compound and its organic electroluminescence device using the compound

Also Published As

Publication number Publication date
KR102673121B1 (en) 2024-06-07
WO2018070835A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
KR102715911B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101614599B1 (en) Organic compound and organic electroluminescent device comprising the same
KR20180069475A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR101829108B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20180022190A (en) Organic compounds and organic electro luminescence device comprising the same
KR102577617B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20190058748A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20230078604A (en) Organic compounds and organic electro luminescence device comprising the same
KR20220020853A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102559589B1 (en) Organic compound and organic electroluminescent device including the same
KR101827067B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20170016701A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102559638B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20150103968A (en) Organic compounds and organic electro luminescence device comprising the same
KR101641411B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR102307237B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102673121B1 (en) Organic compound and organic electroluminescent device using the same
KR102692891B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR102507371B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102283306B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20170114369A (en) Organic compound and organic electroluminescent device using the same
KR102339569B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102307236B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102389616B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR102656919B1 (en) Organic compounds and organic electro luminescence device comprising the same

Legal Events

Date Code Title Description
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant